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ABSTRACT Investigation of novel mitoNEET ligand NL-1 as a therapeutic
for Cerebral Ischemia and Reperfusion Injury
Pushkar Atul Saralkar, M.S.
Cerebral ischemia reperfusion injury, a common type of stroke, is a neurodegenerative disorder
which is the leading cause of permanent disability in the United States. The underlying
pathophysiology of ischemic stroke involves an occlusion in the vasculature supplying oxygen and
glucose to the brain tissue, leading to infarction and eventual necrosis in the brain. MitoNEET is
an outer mitochondrial protein that plays a role in the cellular bioenergetics and its redox
physiology. Although its endogenous ligands are under investigation, mitoNEET binds molecules
with a thiazolidinedione moiety, such as NL-1. This dissertation investigates NL-1 as a potential
cytoprotective agent, and its possible use as a stroke therapeutic. After establishing the binding of
NL-1 to mitoNEET, the effects of the drug on cellular bioenergetics as well as the mitochondrial
function were studied. Upon the successful preliminary studies, NL-1 was formulated into a
polymeric nanoparticle system and its efficacy evaluated in an in vitro stroke model on endothelial
cells. The NL-1 loaded nanoparticles were found to reduce the generation of cell damaging
peroxide, which is an important component of the oxidative stress causing milieu. The NL-1
nanoparticles also helped improve cell survival by decreasing the apoptotic cell population, one of
the principal modes of cell damage following stroke. To evaluate promising in vitro results in vivo,
a two-hour transient middle cerebral artery occlusion model was utilized. Analysis of brain
sections after 24 hours showed a significantly reduced infarct volume and hemispheric swelling
following treatment with NL-1 and NL-1 nanoparticles. Reduced levels of IgG extravasation were
seen in treated animals compared to controls, after a 72-hour period following treatment.
Qualitative analysis also revealed decreased staining area and intensity for GFAP, nitrotyrosine
and 4-hydroxynonenal. Future studies need to be focused on determining the exact mechanism of
action of NL-1 in the mitochondrial axis, which could help improve its dosing. A long-term study
with focus on cognitive and motor neurological outcomes, following treatment with NL-1 would
be the primary translational future aim. In summary, this dissertation establishes the preliminary
basis for use of NL-1 as a stroke therapeutic which could compliment the current therapy in
alleviating the effects of reperfusion injury.
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CHAPTER 1
INTRODUCTION
Stroke is a common neurodegenerative pathology that leads to a gradual loss of cerebral
functions. It is among the leading causes of deaths and the leading cause of permanent disability
in the United States. About 800,000 Americans suffer from stroke each year, which results in
150,000 deaths, and the financial burden on the health care system is over $33 billion USD1. About
80% of the strokes are ischemic in origin, wherein, an occlusion in the blood vessels leads to
inadequate supply of oxygen and essential nutrients such as glucose to the brain tissue.
The only FDA approved treatment for ischemic stroke is the administration of tissue
plasminogen activator (tPA), which is a thrombolytic agent. Treatment with tPA and other
investigational thrombolytic agents is aimed at dissolving the clot that is occluding blood flow.
Although seemingly counterintuitive, a resumption in blood flow has the potential to cause greater
damage in most patients. This event, called reperfusion, triggers multiple downstream cascade of
events that can exacerbate the toxic effects on the components of the neurovascular unit. The
‘reperfusion injury’ can increase the size of infarct and is the principal reason for the hemorrhagic
edema which can often be fatal2. The consequences of stroke such as long-term disability often go
unmitigated due to the lack of effective neuroprotective strategies addressing the issue of
reperfusion injury3. Although the literature is replete with over 1000 candidate compounds tested
with the hopes of eventual clinical use, not a single compound has been successfully translated
into a viable clinically useful drug4.
MitoNEET is a fairly recently discovered protein present in the outer mitochondrial
membrane. This 14 kD protein was identified in 2003 by Colca et al., as the mitochondrial target
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for the anti-diabetic drug pioglitazone5. Pioglitazone is a drug from the thiazolidinedione category,
whose target for diabetic therapy is the PPARγ receptor. Thus mitoNEET is an off-target binding
partner of this class of drugs. Subsequent investigations revealed the crystal structure of
mitoNEET, and the protein was found to contain two iron-sulfur clusters, which are involved in
electron transfer and redox processes6. MitoNEET has been implicated to play a role in numerous
pathologies, including the neurodegenerative CNS disorders such as Alzheimer’s and Parkinson’s
Disease7,8. The efforts to develop a mitoNEET ligand that lacked PPARγ activity, led our group to
synthesize thiazolidinedione analog, NL-19. This ligand has been shown to have a cytoprotective
effect on cardiac stem cells by combating oxidative stress induced cell death10. Together, the role
of mitoNEET and the potential of NL-1 lays the premise for its use in the neurodegenerative
disease of stroke, wherein the mitochondria play a pivotal role in the pathophysiology. NL-1 is a
ligand for an unexplored stroke target, and we hypothesize that by improving on cellular
bioenergetics and mitigating cell death, NL-1 could provide an effective and improved therapy for
stroke.
In this dissertation, we investigate the role of the mitoNEET ligand NL-1 as a potential
therapeutic agent in treatment of stroke, mainly the consequences arising from reperfusion injury.
We start with the basis establishing NL-1 as a cytoprotective agent, acting on cellular
bioenergetics. We then propose a polymeric nanoparticle system for effective NL-1 delivery, and
explore the efficacy of the drug and nanoparticles on in vitro stoke models. Further, we determine
if the in vitro success could be translated in vivo, in a rat stroke model.
Chapter 2 reviews the pathophysiology of stroke. We discuss the multiple facets of cell
damage associated with stroke such as oxidative stress, apoptosis, inflammation, edema and BBB
disruption. With the research in understanding the protein mitoNEET still in a nascent stage, we
2

also discuss the progress made so far with the structural features of mitoNEET, its role in general
cellular physiology as well as its potential role in pathophysiology.
Chapter 3 focuses on preliminary studies on NL-1 as a candidate drug. We establish the
binding of NL-1 to mitoNEET, without the extraneous PPARγ effects. Further, we test the effect
of NL-1 on mitochondrial membrane potential during oxidative stress, and its effect on cellular
respiration as function of oxidative phosphorylation and pH.
The development, characterization and efficacy studies for PLGA nanoparticles for NL-1
have been described in Chapter 4. We discuss the formulation and optimization of NL-1 loaded
PLGA nanoparticles. We further highlight the characterization of this formulation for particle size,
surface charge, physical state and drug release. The two primary mechanisms of cell death
following stroke and reperfusion injury with a mitochondrial dimension include the generation of
ROS and induction of the apoptosis cascade11. The efficacy of the formulation is determined using
an in vitro hypoxia-reperfusion model, and its effect on peroxide generation and apoptosis is
studied. Finally, we address the safety of the formulation in this chapter.
In Chapter 5, we aim to evaluate the NL-1 nanoparticle formulation to a pre-clinical level.
We determine the efficacy of NL-1 nanoparticles in a rat transient middle cerebral artery occlusion
model of stroke. The effect of the treatment is studied on infarct size as well as the brain edema,
which is a hallmark feature of the reperfusion injury. We also evaluate the outcome of these effects,
and check if they are translated at a behavioral level. The impact of NL-1 therapy on the mediators
of cell damage in stroke is explored by performing immunohistochemistry on brain slices.
In summary, this dissertation explores a new treatment strategy for cerebral ischemia and
reperfusion injury, a common form of stroke. We aim to establish NL-1, a first in class mitoNEET
ligand as a therapeutic agent for stroke. Overall, this would be the first study targeting the protein
3

mitoNEET to achieve improved cell survival and neurological outcomes at an in vitro and
preclinical level, respectively, following stroke. It lays the groundwork for future investigation of
a possible synergy between thrombolytic agents and mitoNEET ligands for improved mitigation
of this dreadful condition.
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2.1. Ischemic Stroke
Cerebral ischemia is a consequence of occlusion of the blood flow to the brain, leading to depleted
supply of glucose and oxygen to the cerebral tissue. Ischemic stroke, which accounts for about
80% of stroke cases, can be either focal or global1. The focal cerebral ischemia occurs in a specific
6

region of the brain, and is characterized by an ischemic core and an ischemic penumbra
surrounding the core. Global ischemic event begins in the arteries of lower regions such as the
head and neck region. Global cerebral ischemia leads to widespread brain damage and is often
fatal. Cerebral ischemia in the brain can be divided into two regions, that vary in blood flow
occlusion and hence the pathophysiology. The central area that has the highest reduction in blood
flow and undergoes irreversible damage is called the ischemic core. The area surrounding the core
is called the penumbra which has a reduced blood flow, but can be salvaged with timely
intervention2.
2.2. The energy crisis and excitotoxicity
A dearth of essential nutrients leads to a dysfunctional electron transport chain, which eventually
affects the generation of ATP. As a result, cellular respiration begins to shift from aerobic to
anaerobic. Decreased ATP production also affects the functioning of energy-dependent transport
pumps such as the Na+/K+, Na+/H+ and calcium pumps. The sodium ion concentration inside the
cells increases, while the potassium ion import is reduced. Calcium reuptake in the endoplasmic
reticulum is inhibited leading to a rise in the cytoplasmic calcium ion levels. High cation levels
subsequently increase the osmolarity of the cell, leading to water influx in the cells and their
swelling. Accumulation of hydrogen ions lowers the cellular pH leading to lower enzyme activity
and clumping of nuclear chromatin. Protein synthesis is also affected as a result of ribosomal
detachment3. ATP imbalance also affects the functioning of reuptake pumps of neurotransmitters
such as glutamate, leading to their prolonged presence in the synapses. Glutamate is an excitatory
neurotransmitter that acts on the NMDA and AMPA receptors, and cell damage due to glutamate
excitotoxicity is often seen in stroke. The permeability of these receptors to calcium ions is
increased. A build-up of intracellular calcium activates the mediators of apoptosis and necrosis.
7

Excess calcium in mitochondria leads to the loss of membrane potential and enhanced permeability
of the mitochondrial membranes, promoting apoptosis. A disturbed calcium homeostasis loosens
the BBB tight junctions, increasing permeability4,5.
While most of the manifestations of stroke are a result of neuronal damage, the factors contributing
to the pathophysiology of stroke are not limited to neurons. These encompass a complex interplay
between the components of the neurovascular unit that forms the BBB such as the endothelial cells,
astrocytes, pericytes, microglia and the physiological markers emanating from these cells.
2.3. Oxidative stress in stroke
The reactive oxygen species (ROS) and reactive nitrogen species (RNS) mediate the cell damage
associated with oxidative stress. The ROS and RNS generation in ischemic and reperfusion phase
is very heterogeneous, due to the variable blood flow in the stroke core and the penumbra.
Mitochondria are the predominant intracellular source as well as the target of oxidative stress.
Indeed, a post-stroke upregulation in mitophagy to rid the neurons of damaged mitochondria has
been reported6. Their sources are primarily enzymatic, involving the enzymes such as the xanthine
oxidase system, NADPH oxidase system, nitric oxide (NO) system and the electron transport
chain. The electron transport chain (ETC) generates ATP, using oxygen during the process. Most
of the oxygen used is converted to water molecules, however, a small amount is reduced to form
superoxide radicals. Superoxide radicals (O2.-) are converted to hydrogen peroxide by the enzyme
superoxide dismutase. The primary enzymes of xanthine oxidase system include xanthine
dehydrogenase and xanthine oxidase. During ischemia, both are shifted to xanthine
oxidoreductase. Upon reperfusion, this enzyme system initiates the metabolism of hypoxanthine
to xanthine and further to uric acid. In this process, oxygen acts as the final electron acceptor, and
ROS such as superoxide and hydrogen peroxide are released, causing oxidative stress and
8

downstream inflammatory events3. The expression of NADPH oxidases (NOX enzymes) has been
reported to be upregulated after an ischemic event7. The increased activity of NOX enzymes leads
to the production of superoxide radicals, that eventually forms hydrogen peroxide8.
Superoxide also contributes to RNS formation and turns cell organelles alkaline, whereas,
hydrogen peroxide affects the functioning of tyrosine and serine-threonine phosphatases. Hypoxic
environment induces the hypoxia inhibitory factor 1α (HIF-1α) to promote NOX enzyme
activation, and a positive feedback loop is established with increased oxidative stress, HIF-1α
production and NOX enzyme activation. NOX activity is also enhanced by cytokines during the
reperfusion process. NO is a free radical generated by the enzyme nitric oxide synthase (NOS).
The subtypes of NOS involved depends on the cell type. Neurons use neuronal NOS, glial cells
use inducible NOS, while endothelial NOS generates NO from endothelial cells. While NO from
endothelial cells promotes vasodilation and has protective tendency, neuronal and glial NO
contributes to cerebral damage9. NO reacts with superoxide radicals to form peroxynitrite
(ONOO), a powerful oxidant. Peroxynitrite has about 400-fold faster membrane permeability as
compared to superoxide radical, providing it an easy access to its intracellular biological targets10.
One of the reactions peroxynitrite is involved in is the tyrosine nitration to form nitrotyrosine (NT),
which is used as a marker for peroxynitrite11. Under ROS-RNS influence and in conjunction with
plateletderived growth factor (PDGF)-β, pericytes undergo contraction which leads to capillary
constriction and further impedes blood flow in the cerebral vasculature12. The constriction of
pericytes is more prominently seen during the reperfusion phase, and is a contributing factor to
reperfusion injury12,13.
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2.4. Apoptosis induced cell death in stroke
Cell damage and death in stroke is bimodal, and can occur due to the consequences of both
ischemia or reperfusion. Ischemic event can result in build-up of metabolites and cellular acidosis,
whereas reperfusion usually triggers ROS generation and recruitment of inflammatory mediators,
all of which are responsible for cytotoxicity. Apoptosis, the process of programmed cell death, is
initiated during both phases. Both, hypoxic events during ischemia and ROS generation during
reperfusion can initiate cell apoptosis14. An overload of ROS tends to exhaust the scavengers such
as superoxide dismutase15. This could in turn promote apoptosis, as superoxide dismutase has been
reported to prevent the early release of cytochrome c from the mitochondria after transient focal
cerebral ischemia16. Mitochondrial damage varies in transient ischemia compared to permanent
ischemia, indicating the effect of reperfusion. The primary difference reported shows that
reperfusion injury can cause disintegration of mitochondria after 24 hours, while permanent
ischemia leaves mitochondrial shapes intact, albeit swollen17. Intracellular calcium ion build up
has been shown cause mitochondrial swelling in neurons to an extent, and subsequently causing a
moderate release of cytochrome c18. Calcium induced mitochondrial swelling has been shown to
be calcium ion concentration dependent. The loss of membrane potential worsens with reperfusion
period, reaching an ebb at 24 hours19.
Apoptosis occurs via two pathways: extrinsic and intrinsic. The extrinsic pathway is activated by
external receptors and ligands, the prominent among which is the Fas-ligand. This pathway
activates the initiator caspases 8 and 10 that mediate the cell death. The intrinsic pathway of
apoptosis is initiated at the mitochondrial level, and is more likely to be involved in stroke as it is
activated by hypoxia, cellular toxins and damage to mitochondrial membrane. Ischemia
reperfusion injury enhances the activity of pro-apoptotic members of the Bcl-2 protein family.
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Cytoplasmic pro-apoptotic Bad binds the anti-apoptotic Bcl-2 and Bcl-XL proteins attenuating
their activity. Moreover, the formation of mitochondrial channel involving cytoplasmic Bax and
mitochondrial membrane protein Bak is promoted. The Bax-Bak channel allows the release of
cytochrome c from mitochondria. The protein Bid that promotes this channel formation has been
reported to be regulated by ROS levels20. Cytochrome c binds apoptotic protease activation factor1
(Apaf-1) to then form the apoptosome, which activates the initiator caspase-9. Caspase-9 finally
activates the effector caspases such as caspase-3 and 7. Caspase-3 mRNA expression was found
to be upregulated in neuronal cells in ischemia models21. A second form of cell death that has been
reported following ischemia and reperfusion injury is necroptosis, showing a death pattern similar
to necrosis which is characterized by plasma membrane permeation and organelle swelling, and is
a result of excess external stress. Ischemia-reperfusion also induces cell autophagy.
2.5. Stroke and inflammation
Inflammatory events are initiated soon after the onset of focal cerebral ischemia, and subsequently
worsened following reperfusion. Inflammatory events are mediated by the components of
neurovascular unit as well as neutrophils, leukocytes and dendritic cells22. The BBB serves as a
barrier to the brain entry of leukocytes. However, under inflammatory conditions, this barrier
function is compromised. The pro-inflammatory mediators released during the early acute phase
of ischemia induce the endothelial expression of adhesion molecules such as ICAM-1 and
selectins, promoting leukocyte infiltration and adhesion. Over the course of time in the subacute
phase, the infiltrating leukocytes amplify the inflammatory and ROS population. Amongst the
infiltrating leukocytes, neutrophils dominate the early phase of up to a few hours after ischemia23.
Mast cells secrete vasoactive substances and gelatinase granules and contribute to the overall BBB
disruption24. In a rat stroke model, mast cells have been shown to regulate brain swelling and
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neutrophil accumulation in the early phase25. There are reports of infiltration of dendritic cells in
the brain after an ischemia, which could worsen stroke outcomes by heightening a CNS T-cell
immune response, and an overall immunodepression in the body due to a decrease in dendritic cell
population in the systemic circulation26. Ischemic events lead to activation of the cerebral immune
system, most notably the activation of the microglial cells. Microglia represent the predominant
population amongst the macrophage-like cells, and have a heightened activity during the first few
days after ischemia23. While activated microglia can eliminate the harmful excitotoxins, they also
display enhanced phagocytosis, release of pro-inflammatory cytokines via Toll-like receptor
(TLR2 and TLR4) activation, TNFα, IL-1β, Iba-1, CD40 among others, which cause damage.
Apart from microglia, reactive astrocytes also contribute to the pro-inflammatory milieu.
Astrocytes in an ischemic environment show an upregulation of glial fibrillary acidic protein
(GFAP) denoting an inflamed state. The glial scar formed by inflamed astrocytes often demarcates
the healthy brain tissue from the ischemic zone22,27.
CD4+ and CD8+ T-lymphocytes also contribute to the inflammatory disequilibrium in stroke by
releasing pro-inflammatory cytokines28.
2.6. Edema in stroke
A hallmark feature of cerebral ischemia and reperfusion injury is the damage resulting from brain
swelling, or edema. The CNS cells have higher intracellular concentrations of potassium ions, and
low concentrations of sodium and calcium ions. Under normal physiologic conditions, the osmotic
concentrations of intracellular and extracellular fluids are maintained. However, in the case of an
imbalance of solute concentrations, a transmembrane osmotic gradient is generated, and because
the cell membrane is freely permeable to water, this gradient causes a flow of water into or out of
the cell to attain an osmotic balance. This leads to swelling or shrinkage of the cell, depending on
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the directions of water flow. Lack of energy in ischemia leads to the dysfunction of ion pumps,
and cell swelling occurs due to the electrolyte imbalance with excess buildup of intracellular
sodium ions, and extracellular potassium ions, and subsequent water influx from the extracellular
space.
Ischemia-induced edema can be broadly classified in having cytotoxic, vasogenic and ionic
origins29. The primary component of the neurovascular unit that accounts for cytotoxic edema are
the astrocytes, due to their larger populations. Cytotoxic edema leads to an alteration of ionic
gradient, mainly via secondary active transport (co-transporters) or passive transport of ions.
Glutamate excitotoxicity at NMDA and AMPA receptors also contributes to the abnormal influx
of extracellular ions. The influx of sodium ions, followed by chloride ions accumulate in the
intracellular space. This triggers an influx of water through the aquaporin channels to maintain the
osmotic balance. Aquaporin channels are key mediators of the water influx. Astrocytic AQP4
channel activity, which is upregulated by excess glutamate is known to facilitate increased water
influx27. AQP4 overexpression leads to swelling of astrocytes and activates microglia, leading to
inflammatory consequences30. AQP4 can thus contribute to the transition of cytotoxic edema to
vasogenic edema31.
The cytotoxic edema occurs within the boundaries of the CNS, and thus, only redistributes the
ionic and water within. It does not alter the total brain volume, which is seen in stroke. The increase
in brain volume is primarily mediated by endothelial cells, which contribute to the ionic and
vasogenic edema. Ionic edema, which precedes the vasogenic edema is facilitated by changes in
the BBB. Due to the events surrounding the cytotoxic edema, the extracellular space of the brain
suffers a shortage of water and ions. The resulting gradient triggers the movement of ions and
water from the vasculature into the brain extracellular space. Ionic edema occurs early during
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ischemia when the BBB tight junctions are intact, and thus, the ionic edema fluid lacks plasma
proteins. The toxic mediators of ischemia also enhance the endothelial cell permeability by
increasing the expression of ion transporters.
The secondary phase of endothelial cell mediated edema is the vasogenic edema, which is a
delayed phase occurring a few hours after the onset of ionic edema32. The primary difference
between the two phases is that the vasogenic edema begins when the BBB tight junctions suffer a
breakdown33. Vasogenic edema predominates during the reperfusion phase, does not lead to cell
swelling and the edema fluid is plasma protein rich34. It is caused by a multiple factors acting
simultaneously to breakdown the BBB and include the likes of VEGF, MMPs, metabolites of
arachidonic acid and inflammatory cytokines among others29,35,36.
Cerebral edema during ischemia and reperfusion leads to increased brain swelling and an elevated
intracranial pressure. It is a leading consequence of the reperfusion injury and an important factor
contributing to fatalities related to stroke37.
2.7. The BBB in stroke
The complex interplay between oxidative and inflammatory stress has a deleterious effect on the
integrity of the BBB and causes barrier opening. The BBB disruption is known to be more severe
in transient ischemia compared to permanent occlusion38. This is indicative of the damage
reperfusion can cause. The opening of BBB after transient ischemia has been demonstrated to be
biphasic, with peaks occurring around 3 and 48 hours post-reperfusion commencement39,40. The
BBB in the ischemic core is prone to irreversible damage, whereas the BBB in the penumbra region
is known to be mildly damaged and can be salvaged41,42. The BBB permeability in stroke was
studied using an MRI contrast agent such as Gd-DTPA by applying Patlak plot analysis to the
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influx of the agent, wherein elevated influx rate constant (Kin) values were observed for Gd-DTPA
and sucrose, which is normally impermeable.43. MRI imaging in stroke patients has revealed that
the BBB is most permeable during 6-48-hour period after the onset of ischemia, and the leakage
was seen for up to 90 hours after the ischemic onset44. Permeability surface area product was also
found to be increased in patients with delayed infarction seen in subarachnoid hemorrhage45. Raja
et al. compiled a comparative review focusing on the patient BBB permeability in disease states,
measured by different groups using dynamic contrast enhanced magnetic resonance imaging46.
The permeability coefficient Ktrans for the imaging agent, calculated based on the Patlak model,
was used as a measure of BBB permeability. The Ktrans values indicated an almost four-fold higher
permeability in stroke as compared to early AD in normal appearing white matter.
Enhanced BBB permeability and tight junction disruption after stroke occurs through the mediation
of multiple factors which include immune cells, cytokines, chemokines, micro-RNAs and the
mitochondria47. Inflammatory mediators such as IL-6 and TNF-α downregulate ZO-1 expression
and its association with occludin, thereby reducing the transendothelial electrical resistance. They
also cause phosphorylation of tight junction proteins such as claudin-5 and ZO1, affecting their
functioning48. Pericytes secrete mediators such as matrix metalloproteases that loosen the BBB
tight junctions, aiding in infiltration of leukocytes in the cerebral vessels. The BBB disruption by
MMPs occurs as a biphasic event49. MMP-2, in conjunction with HIF-1α, participates during the
initial hypoxic phase. The later phase, which occurs about 24-48 hours post the initial ischemic
event, is primarily regulated by MMP-3 and MMP-9. Overall, the proteases such as MMPs lead to
a dysfunctional BBB, and are responsible for the hemorrhagic events following a stroke.
Peroxynitrite is known to cause BBB disruption in stroke50. Another major source of MMPs are
neutrophils and thus, neutrophil infiltration following stroke aggravates BBB damage51,52.
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Microglia upregulate the cell adhesion molecules such as ICAM-1, P-selectin, VCAM, thereby
promoting leukocyte infiltration53.
The breakdown of BBB is often attributed to be the reason of transformation of ischemic stroke to
a hemorrhagic one, especially after t-PA administration54. The highest risk of hemorrhagic
transformation exists between 24-48 hours after onset of ischemia, when the BBB exists in a highly
permeable state55. Thus, a BBB dysfunction of a heterogeneous nature is seen in stroke and
facilitates the eventual grave consequences of stroke such as edema and hemorrhage.

2.8. The mitoNEET protein
As the powerhouse of the cell, mitochondria play a vital role of ATP synthesis and nucleotide
production. During this process and beyond, the mitochondrial constituent elements contribute to
a host of biochemical and physiological processes that could impact the cellular microenvironment,
as well as the organ systems. One such mitochondrial protein that has drawn attention in recent
years in mitoNEET. The efforts into investigation of the off-target actions of thiazolidinedione
category of drugs used to treat diabetes led to the discovery of mitoNEET. These drugs, such as
pioglitazone, were found to demonstrate effects that were not downstream of their intended target,
the PPARγ receptor. Colca et al., used tritiated pioglitazone and a photoaffinity cross-linker, and
identified a binding site for the drug in mitochondria56. Using size exclusion chromatography, the
protein was isolated and identified by a combination of mass spectrometry and amino terminal
sequencing. This protein, with a molecular weight of under 17kDa, was found to contain a
characteristic Asn-Glu-Glu-Thr (NEET) sequence. Since it was isolated from mitochondrial
fractions it was subsequently named mitoNEET. The binding of pioglitazone to mitoNEET was
speculated to be responsible for its actions, such as increased lowering of lipid levels as compared
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to rosiglitazone, which happens to be a more potent agonist of the PPARγ receptor. In the years
following its discovery, mitoNEET has been the subject of study by various research groups.
2.9. MitoNEET structure and the iron-sulfur cluster
The structural features of mitoNEET started to be elucidated soon after its discovery. Wiley et al.,
used bioinformatics analysis and found that mitoNEET belonged to a family of proteins containing
the CDGSH-type zinc finger57. The protein, when expressed by the recombinant technology, was
found to be red in color. Further metal analysis revealed that, although it contained the zinc finger,
zinc was present only in trace amounts. Instead, mitoNEET was found to have a presence of iron
as the predominant metal, which was 1.6 mole per mole of the His-tagged mitoNEET. The
mitochondrial localization of mitoNEET was confirmed by generation of an analog that lacked the
first 32 amino acids from the N-terminal. The lack of mitochondrial presence of the analog
indicated that mitoNEET was localized to mitochondria by its N-terminal. Further studies
established the localization in the outer mitochondrial membrane and cytoplasmic orientation of
mitoNEET. The same group also found that iron was present as a 2Fe-2S iron sulfur cluster58.
Although the cluster is found in other proteins such as ferredoxin, the combination of amino acids
that bind this cluster make mitoNEET and its family members unique. In mitoNEET, the 2Fe-2S
cluster is bound by three cysteines and one histidine residue. It was also found that the cluster is
labile to be released at pH of 6 or lower. The reason for this lability has been attributed to the
protonation of His-87 that in turn, leads to cluster release. The pH sensitivity of the cluster and the
contribution of His-87 was further established using resonance Raman spectral analysis of
mitoNEET at varying pH values59. Binding of pioglitazone leads to stabilization of the 2Fe-2S
cluster and prevents its release60.
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Around the same time, the crystal structure of mitoNEET was studied by Lin et al. and Paddock et
al., revealing a homodimeric structure with superimposable subunits60,61. Hydrophobic interactions
and water molecule mediated hydrogen bonding contribute to the dimerization of the monomers62.
Lys-55 was found to be one of the conserved residues in eukaryotic mitoNEET contributing to the
hydrogen bonding network63. Each monomer of mitoNEET binds one 2Fe-2S cluster, and thus
mitoNEET as a whole contains two such clusters, separated by a distance of 16 Å. The cluster
binding region was found to contain an amino acid sequence which was unique to this family of
proteins: (hb)-C-X1-C-X2-(S/T)-X3-P-(hb)-C-D-X2-H. The cluster is bound between the amino
acid residues 71 through 87. MitoNEET is a vase shaped protein with a narrow central region.
Hydrophobic residues predominate the central region, whereas charged residues are present around
the cluster binding region (bottom), and the β-cap domain at the top. Thus, mitoNEET is polar at
the top and the bottom with a hydrophobic region in between. MitoNEET exhibits evolutionary
conservation in its structure across species of mammals, plants and thermophilic bacteria64,
showing a possible important physiological role. The cytoplasmic tethering arms of mitoNEET
were found to be flexible in nature, allowing the cytoplasmic portion of the protein to attain two
different conformations65. Most of the studies geared toward crystal structure have centered on the
structure of mitoNEET in its native form. However, a recent study by Geldenhuys et al., has
revealed the crystal structure of mitoNEET bound to a ligand66. The ligand used in this study was
furosemide, which has a benzoic-sulfonamide-furan structure. This could potentially help in future
design of novel mitoNEET ligands that can be used as therapeutic agents.
An EPR analysis of the protein suggests that the two clusters might be involved in intramolecular
electron transfer67. A redox analysis of the iron-sulfur cluster was performed using protein film
voltammetry, with and without thiazolidinedione binding68. In the wild type protein, the binding
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of pioglitazone and rosiglitazone reduces the midpoint potential of the cluster from around 0 mV
to -100 mV, near neutral pH. However, when mutant form of mitoNEET was used wherein the
His-87 was replaced by a cysteine, no change in the midpoint potential was observed, indicating
the importance of the His-87 residue in thiazolidinedione drug binding to mitoNEET. The effect
of replacing the His-87 with a cysteine on the cluster properties was studied by Conlan et al69.
Cluster co-ordination by four Cys residues imparts greater stability to the cluster within the protein.
However, the pH sensitivity of the cluster is not altered in the mutant as compared to the wild type
protein. This finding contradicts the prior theory that protonation of His-87 is responsible for
cluster release at an acidic pH. It was concluded that the unique co-ordination pattern seen in wild
type protein could be a possible evolutionary effect, as four Cys ligands would hinder the transfer
of electrons to partners in the cytosol. Subsequently, it was found that His-87 was not the sole
contributing factor to pH dependence of cluster stability, with other residues namely Lys-55,
Ser77, and Asp-84 also known to play a role63. This shows that it is not just the cluster coordinating
residues but also the residues from the hydrogen bonding network that contribute to the stability
of the 2Fe-2S cluster.
The stability of the cluster is also influenced by its oxidation state, with the reduced form being
more stable as compared to the oxidized form63. The polarity and strength of the His-87 and iron
co-ordinate bond also influences cluster stability in mitoNEET70. Higher polarity and lower bond
strength contribute to cluster lability. When His-87 is protonated, the bond between the histidine
and iron is more polar and weaker. The hydration of histidine promotes its protonation, indirectly
affecting the cluster lability. In the protonated state, mitoNEET forms hydrogen bonds with water;
whereas in the deprotonated state, it hydrogen bonds with Lys-55. This lysine residue has an
orientation state that favors hydration of His-87. The presence or absence of the cluster can also
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affect the overall structure of mitoNEET. Removal of cluster from one monomer not only leads to
unfolding of the α-helix of that monomer, but also affects the other monomer70. Loss of both
clusters could lead to a loss of secondary structure folding. This could lead to a loss of mitoNEET
function and could potentially be a factor in cancer and neurodegenerative diseases. MitoNEET
can alternate between an unstructured apo-form without the cluster, and a cluster-bound folded
form71. MitoNEET receives the cluster from the mitochondria. The efficient functioning of the
iron-sulfur cluster assembly enzymes and its export mechanisms from the mitochondria are
inevitable to keep mitoNEET in a structured form and prevent its eventual proteasomal
degradation.
A model of mitoNEET 2Fe-2S cluster was shown to mediate proton coupled electron transfer
(PCET), and the His-87, which undergoes protonation at acidic pH, has been thought to play an
important functional role in the PCET process72. The exposure of nitrogen of the histidine
imidazole on the protein surface facilitates an easy protonation of the residue. MitoNEET displays
a difference in colorimetric absorption maxima depending on its oxidation state. When mitoNEET
exists in an oxidized state, an absorption maximum is observed at 458 nm wavelength, and a
minimum is seen at this wavelength when the cluster is in a reduced state73.
2.10. Role of mitoNEET in physiology
MitoNEET has been found to play a vital role in regulation of cellular bioenergetics. The cardiac
cells of mitoNEET knockout mice were found to have a significantly lower respiration rate as
compared to the wild-type57. It was found that the redox potential of mitoNEET 2Fe-2S cluster
could be manipulated over a wide range for the wild type and the His-87, Lys-55, and Asp-44
mutants74. The range encompasses about 700 mV (from -360 mV to +305 mV) which happens to
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span the cellular redox range. This indicated the potential for use of mitoNEET and its mutant
forms as externally administered redox agents.
The cluster transfer from mitoNEET to cytosolic proteins is one of the primary physiological
functions of mitoNEET. Unlike other iron-sulfur cluster containing proteins, mitoNEET can
transfer its iron-sulfur cluster under aerobic conditions as well75. The activity of cytosolic aconitase
was found to be lower upon knockdown of mitoNEET. Further investigation revealed that the
significant reduction in the iron-sulfur cluster transfer to cytosolic aconitase caused the depletion
in activity, which was promptly rescued upon mitoNEET transfection. Transfection with a His-87
mutant did not show similar rescue, once again showing the involvement of the critical residue in
cluster transfer. Coupled with the fact that loss of mitoNEET did not affect aconitase expression,
this study outlined the importance of mitoNEET in function and maturation of cytosolic proteins76.
MitoNEET also plays a role in repairing the cytosolic iron-sulfur cluster of Iron Regulatory
Protein-1 (IRP-1)71, and is a key regulator of cellular iron homeostasis. MitoNEET has been
reported to interact with 1,4-Alpha-Glucan Branching Enzyme (AGBE) in a Drosophila model77.
The Drosophila AGBE assists mitoNEET in IRP-1 repair, keeping it viable for nuclear entry. Using
NMR and UV-visible spectroscopy, it has been determined that mitoNEET transfers the iron-sulfur
cluster to cytosolic recipients in an oxidized form. Upon transfer, the protein changes from a wellfolded holo-form to an unfolded apo-form. The reduced state of mitoNEET has thus been termed
as the dormant state, whereas the oxidized transfer-ready state has been termed as the active state78.
Upon completion of the repair of IRP-1, mitoNEET needs to be brought back to its ‘dormant’
reduced form. This is achieved by an interaction of mitoNEET with a complex of two proteins.
These two proteins are anamorsin and NADPH-dependent diflavin oxidoreductase 1 (Ndor1).

21

Anamorsin-Ndor1 complex thus reduces mitoNEET and halts the repair process that mitoNEET is
involved in79.
The cluster transfer details were further studied using apo-ferredoxin, wherein it was found that
only one of the two clusters of mitoNEET are transferred to the apo-protein in a direct manner;
while the second cluster undergoes degradation80. MitoNEET and the acceptor protein form a
transient, unstable complex during the process of cluster transfer. This study also demonstrated
that pH dictates the cluster stability only under anaerobic conditions. The iron-sulfur cluster is
rendered stable under anaerobic conditions, at acidic pH. The cluster transfer to an apo-protein is
also dependent on the pH, and likely allows mitoNEET to act as a pH sensor while transferring the
iron-sulfur cluster. Low pH not only affects the cluster stability, but also lowers the stability of the
holo-mitoNEET dimer. The iron-sulfur cluster was also found to be stable to hydrogen peroxide
exposure in vitro, indicating its role in cell response to oxidative stress.
Apart from its direct interactions with cytosolic proteins, mitoNEET can influence the interactions
of mitochondrion with cytosolic proteins through the regulation of voltage-dependent anion
channel 1 (VDAC1). MitoNEET, in an oxidized form, has been found to bind and gate the
VDAC181. VDAC1 controls mitochondrial respiration, regulates apoptosis, transport of ions and
metabolites between the mitochondrial intermembrane space and the cytosol. The interactions if
mitoNEET and VDAC1 were confirmed using an irreversibly binding inhibitor of VDAC1. The
regulation of VDAC1 by mitoNEET can prove to be vital for mitochondrial homeostasis.
Studies have been performed to determine the effect of binding of endogenous molecules,
especially the ones involved in redox processes, on mitoNEET and the iron-sulfur cluster. Zhou et
al., determined the that upon binding mitoNEET at an acidic pH, NADPH caused the
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destabilization of the cluster and its eventual release from the protein82. Following cluster release,
mitoNEET loses its three dimensional structure. NADPH is thought to interact with the residues
in mitoNEET that in turn interact with the cluster binding residues. Upon loss of these interactions,
destabilization of the cluster occurs. These events have been speculated to be contributing factors
in pathophysiology of metabolic diseases, wherein mitoNEET might act as an NADPH sensor.
Subsequently, Zuris et al., studied the effect of NADPH binding on the ability of mitoNEET to
transfer the cluster83. It was found that NADPH binding at a Ki of 200 μM inhibited the transfer of
the cluster to an apo-acceptor protein. The primary residue mediating the NADPH actions of
cluster transfer was found to be the cluster interacting residue Asp-84. NAPDH also shifts the
redox potential of the cluster. These findings give more substance to the role of mitoNEET as a
sensor of NADPH, the levels of which could be altered in disease states. Lowered NADPH levels
in a pathophysiological condition would then lead to cluster release from mitoNEET. Thus
NADPH can modulate the cluster levels in mitoNEET and cytoplasm, as well as the mitoNEET
structure. Apart from NADPH, Flavin nucleotides have also been shown to display specific
interactions with mitoNEET84. Reduced flavin mononucleotide (FMN) was found to reduce
mitoNEET cluster under aerobic and anaerobic conditions. A combination of EPR and molecular
docking studies showed that FMN, and not flavin adenine dinucleotide (FAD) has the reducing
ability; and FMN binds mitoNEET between the transmembrane portion and the iron-sulfur cluster.
This was deemed ideal for electron transfer between the biomolecule and the cluster. This is yet
another example of mitoNEET acting as a metabolic regulator.
MitoNEET also has a stimulatory effect on cellular glycolysis85. During the reduction reaction of
FMNH2, catalyzed by flavin reductase, mitoNEET also undergoes reduction upon binding of
cytosolic NADH, which in turn gets oxidized. Oxidation of NADH is necessary for sustenance of
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glycolytic process. Thus mitoNEET is thought to contribute to enhance glycolysis. Ubiquinone-2,
which is an important biochemical constituent of the respiratory cycle milieu, was found to oxidize
the reduced clusters of mitoNEET under aerobic and anaerobic conditions. Ubiquinone-2 has a
strong presence in inner and outer mitochondrial membranes, and due to its superior efficiency in
oxidizing clusters, it has been proposed to be an intrinsic electron acceptor of mitoNEET clusters.
The oxidation of mitoNEET by ubiquinone-2 under anaerobic conditions is 500 times faster than
oxygen, with a rate constant of 3000 M-1s-1 as compared to 6 M-1s-1 for oxygen86. Under aerobic
conditions, ubiquinone-2 causes rapid oxidation of mitoNEET clusters, preventing their reduction
by FMNH2.
The importance of mitoNEET in the formation of mitochondrial network has also been studied87.
Mitochondria often assemble into groups of two or three. Using electron microscopy, it was seen
that when mitoNEET was knocked down, the formation of intermitochondrial junctions was
significantly lowered as compared to wild type cells. Upon overexpression of mitoNEET, an
increase in the intermitochondrial junction formation and mitochondrial clustering was observed,
confirming the necessity of mitoNEET in their formation. The mechanism for mitochondrial
tethering has been suggested to be linkage of two mitoNEET proteins from separate mitochondria.
The respiratory capacity of the cells was found to be reduced due to decrease in the mitochondrial
numbers. However, mitochondrial size was not seen to be affected by mitoNEET knockdown.
MitoNEET was also not found to be relevant in establishment of contact between mitochondria
and endoplasmic reticulum.
Landry et al., studied the redox effects of biological thiols and hydrogen peroxide on mitoNEET88.
MitoNEET cluster can be partially reduced by monothiols such as glutathione and L-cysteine,
whereas dithiothreitol and E. coli thioredoxin-1 cause complete reduction. The cluster reduction is
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reversible, and they can be oxidized by hydrogen peroxide. This is suggestive of mitoNEET’s role
as a sensor for the levels of redox compounds and ROS. Upon binding mitoNEET, pioglitazone
inhibits the thiol mediated reduction of the iron-sulfur clusters. Subsequently, the same group
showed that human glutathione reductase had the ability to reduce mitoNEET clusters, in a similar
reversible manner89. Their studies with N-ethylmaleimide, which inhibits the activity of the
enzyme on mitoNEET clusters, showed that the redox active disulfide present in the catalytic
center of glutathione reductase was involved in the reduction of the iron-sulfur cluster.
MitoNEET belongs to the family of NEET proteins wherein the 2Fe-2S cluster is coordinated by
three cysteine and one histidine residues. Another member of this family happens to be NAF-1,
which is encoded by the CISD2 gene. The interactions between the two proteins have been studied
by Karmi et al., and it gives us an understanding of the dependence and independence of these
members of the NEET family of proteins90. Using in vivo biomolecular fluorescence
complementation analysis, it was found that mitoNEET and NAF-1 interacted in endoplasmic
reticulum and mitochondria. This interaction was mainly in the form of cluster transfer from an
oxidized form of mitoNEET to a pre-reduced apo-form of NAF-1. It was further stated that
mitoNEET and NAF-1 work complimentarily in the same biochemical pathway, and control the
levels of iron and ROS in the cells. This helps in cell survival and prevention of cellular apoptosis,
having favorable effects in cell survival in neurodegenerative diseases and pro-survival effects in
cancer cells. A possibility of mitoNEET and NAF-1 being a part of cluster transfer relay has also
been proposed. Thus, along with their independent functions, mitoNEET and NAF-1 also work in
a cooperative manner as part of common biochemical processes.
The role of cisd-1 gene in physiological germline apoptosis has been elucidated in a
Caenorhabditis elegans (C. elegans) model91. In C. elegans, this gene encodes for a protein which
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is homologous to mitoNEET (CISD1) and NAF-1 (CISD2) in vertebrates, and retains the 2Fe-2S
cluster. A C. elegans mutant with deletion in cisd-1 coding region displayed germline defects
including reduction in number of differentiated oocytes and distal tip cell migration defects.
Increased numbers of cell corpses within the germline were also observed. The mechanism for cell
death was attributed to apoptotic pathway dependent on CED-13 (pro-apoptotic protein in C.
elegans) function. Thus, CISD family members, mitoNEET and NAF-1, were found to have
prosurvival effects in this model. They are said to work in a co-operative manner.
2.11. MitoNEET in neurodegenerative diseases
The unravelling of the physiological contributions of mitoNEET lead to investigations into its role
in disease conditions. Due to its functional importance at a cellular level, any disruption in its
normal function can potentially be a causative factor in a wide variety of anomalies. We have seen
that the presence of iron – sulfur cluster in mitochondrial proteins is found to be critical to many
cellular functions and disease development. It was found that zinc and iron-sulfur cluster share a
binding site on mitoNEET and excess zinc ions compete with the cluster on that binding site in
mitoNEET, thus prohibiting the assembly of these essential clusters92. Zinc toxicity is known to
be the cause of neurodegenerative conditions such as Alzheimer’s disease and neuronal death
following a stroke93,94,95. High zinc levels were previously found to disrupt iron homeostasis96, and
a likely reason can be narrowed down to its mitoNEET binding.
MitoNEET also plays an important role following spinal cord transection, possibly revealing
mitoNEET as a target for treatment and repair of a spinal cord injury. MicroRNA-127 was shown
to induce neuronal loss via apoptosis, axonal degradation, sensory and motor dysfunction
following spinal cord transection. Such effects of microRNA-127 were also seen on spinal cord
cells in vitro. In these events, a target of microRNA-127 was mitoNEET. Knockdown of
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mitoNEET in vitro lead to similar neurodegenerative effects showing that mitoNEET and
microRNA-127 can be used as therapeutic targets to prevent the exacerbation of neuronal loss97.
MitoNEET has also been identified as a potential target for treating Parkinson’s disease.
MitoNEET knockout mice exhibit mitochondrial dysfunction in their brain. Loss of mitoNEET
decreases striatal tyrosine hydroxylase and dopamine, as a result of which the mice display motor
deficits with shortened strides and lack of balance. Increased iron accumulation is also observed
in striatum in knockout mice, which is a possible precedent for increased ROS levels that contribute
to the Parkinson’s pathology. This shows that mitoNEET has an impact on the neurons that control
movement, similar to the phenotype of Parkinson’s disease, making it a promising target98. The
mitoNEET agonist TT01001 was recently shown to prevent mitochondrial dysfunction by
mitigation of oxidative stress and apoptosis in rats with subarachnoid hemorrhage99.
The role of mitoNEET in postnatal brain development has recently been elucidated100. Quantitative
proteomics on presynaptic mitochondria in postnatal mice found elevated levels of mitoNEET.
Overexpressing mitoNEET displayed a neuronal cell-type specific enhanced mitochondrial
membrane potential, fragment generation, and further increased ATP levels. These changes are
characteristic of mitochondria working at their full potential to fulfill the increased energy demand,
which occurs during brain development at the postnatal stage. Due to its role as a bioenergetics
regulator, and its ROS-protective effects in the developing brain, mitoNEET can be used as a target
for neurodevelopmental disorders.
2.12. The NEET ligand 1 (NL-1)
MitoNEET has binding sites that have been determined to bind thiazolidinedione (TZD or
glitazone) compounds and stabilize the 2Fe-2S cluster. Aided by a combination of molecular
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docking studies and radiolabeled ligands, a novel glitazone analog, the NEET ligand 1 or NL-1
was synthesized101. As mentioned, the glitazones (2, 4-thiazolidiendiones; TZD) have been used
to treat type II diabetes, to lower blood glucose levels. Several of the marketed glitazones were
removed from the market, including troglitazone, due to liver toxicity, and rosiglitazone
(BRL49653C, (±)-5-[[4-[2-methyl-2-(pyridinylamino)ethoxy]phenyl]methyl]methyl]-2,4thiazolidinedione), due to cardiac toxicity. Pioglitazone, AD-4833, (Actos) was first discovered by
Takeda Pharmaceuticals by exploration of substitution patterns on the cyclohexyl ring of
ciglitazone, the prototypical thiazolidinedione in the pharmacological class. The glucose lowering
and amelioration of insulin resistance led to the successful development and FDA approval of
pioglitazone in July of 1999. Pioglitazone was found to be a PPAR-gamma agonist, as its primary
mechanism of action.
The

synthesis

of

NL-1

(5-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl-

2,4thiazolidinedione) was based on a Knoevenagel condensation reaction as shown in Figure 2.2.
Due to the steric hindering of the tert-butyl groups, the reduction of the unsaturated bond requires
LiBH4 and a week reduction to allow for sufficient generation of product. This compound retained
the thiazolidinedione pharmacophore of glitazones, which was thought to be the essential structural
feature for binding mitoNEET. The hydrogen bonding and acceptor groups on the
thiazolidinedione moiety contribute to the drug binding to mitoNEET. NL-1, selectively binds
mitoNEET, without any activity at the peroxisome proliferator-activated gamma (PPAR-γ)
receptor, to which glitazones typically bind.
NL-1 has been successful in reducing rotenone induced cell death by almost 40%. It was also able
to cause uncoupling of mitochondrial respiration, and reduced state III respiration rate by 45%.
The ability of NL-1 to reduce the capacity of mitochondrial complex I has implications in treatment
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of neurodegenerative diseases such as Parkinson’s disease as complex I is shown to generate the
noxious reactive oxygen species (ROS)101. Other applications of NL-1 have been investigated such
as its use in increasing viability of cardiac stem cells introduced in regenerative therapy for
ischemic heart disease. NL-1 was seen to have a short-term cytoprotective effect as an increased
cardiac stem cell survival under oxidative stress was observed. However, this result was not
exhibited by chronic exposure in in vivo studies. Due to the oxidative environment associated with
heart disease, NL-1 is thought to interact with mitoNEET to reduce mitochondrial function
showing lower oxygen consumption rates (OCR) which has been established to reduce ROS. The
specificity of NL-1 toward mitoNEET was confirmed when no significant difference in cell
survival was observed in mitoNEET knockdown cells with NL-1 and vehicle treatments. In
general, NL-1 was able to reduce cardiac stem cell death when exposed to an oxidative
environment102. Due to NL-1’s affinity for mitoNEET, novel drugs targeting mitoNEET may
prove to be beneficial in stem cell therapy. NL-1 has also been tested as a potential drug candidate
in relapsed acute lymphoblastic leukemia103. NL-1 was found to have a dose-dependent cytotoxic
effect in cytarabine-resistant leukemic cell line. The anti-cancer activity of NL-1 was seen in six
different acute lymphoblastic leukemia cell lines, and through hemosphere assay as spheroid
disruption. The mechanism of action of NL-1 has been suggested to be prevention of cancer cell
migration, and induction of autophagy in the cancer cells. NL-1 also showed anti-leukemic activity
in a preliminary in vivo study using a mouse model of acute lymphoblastic leukemia. NL-1 has
been found to be cytotoxic against MCF-7 breast cancer cells with an IC50 value of 7.1 µM, when
the cells were subjected to oxidative phosphorylation using galactose containing growth
medium104.
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For a quantitative approach, a liquid chromatography/tandem mass spectrometry (LC-MS/MS)
assay has been developed to accurately quantify NL-1 levels105. The application of this method
was also demonstrated in a pharmacokinetic analysis of NL-1 levels in serum samples from mice
after a single intraperitoneal dose. The drug was found to reach a maximal serum level within 30
minutes of administration. The NL-1 levels were found to be within the mitoNEET binding activity
range. NL-1 is shown to have similar binding affinity to mitoNEET compared to known
neuroprotectant, pioglitazone106. This fact and the LC-MS/MS technique served useful in a
preliminary pharmacokinetic study of NL-1 that is applicable to a human model of drug delivery.
Using NL-1 as a starting point, many new compounds are being investigated for protective effects
in oxidative environments.
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Figure 2.1: Structures of mitoNEET and NL-1: The homodimeric structure of mitoNEET
(left) with the two iron-sulfur clusters (orange). Structure of the TZD analogs pioglitazone and
NL-1.

Figure 2.2: Synthesis of NL-1 using Knoevenagel condensation reaction
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3.1. Introduction
Ischemic stroke presents significant challenges to human health in United States, and the world.
About 800,000 Americans suffer from stroke each year, which results in 150,000 deaths. Stroke is
the fifth leading cause of death, and the leading cause of permanent disability in the nation1. The
consequences of stroke, i.e. lifelong disabilities due to irreversible death of neurons go unmitigated
due to a lack of efficient neuroprotective strategies in humans2,3. Stroke occurs due to an occlusion
in the vasculature supplying oxygen and nutrients to the brain, causing an energy crisis in that
region which progresses into tissue death. The part of the brain suffering irreversible damage is
called the ischemic core, whereas the area surrounding the core is called the penumbra. The stroke
penumbra consists of the tissue in duress that could be salvaged with a time dependent
intervention4. The current treatment strategy for stroke is aimed at removing the occlusion to blood
flow, and restoring the blood supply to the ischemic penumbra in a timely manner. To date, the
only therapeutic used to restore blood supply is the thrombolytic agent tissue plasminogen activator
(t-PA)3,5. However, when the blood supply is restored and the ischemic tissue is reperfused,
secondary tissue damage is observed, which is generally referred to as ischemiareperfusion (IR)
injury6. The t-PA therapy does not address the local and systemic neurodegeneration associated
with the IR injury. Neurodegeneration occurs due to a complex interplay between factors such as
oxidative stress, apoptosis, inflammatory mediators and excitotoxicity7. A prominent reason for
the rapid and significant mortality after stroke is the onset of edema in the brain8,9. A key player in
the IR injury is the mitochondrion, an organelle central to cellular energetics, apoptosis and ROS
generation. In the literature there have been over 1000 candidate compounds tested with the hopes
of eventual clinical use10. However, not a single compound has been successfully translated into a
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viable clinically useful drug. Therefore, an urgent need exists to develop compounds which can
mitigate the damage from IR injury in brain stroke pathology.
MitoNEET (gene: CISD1) is a recently discovered novel mitochondrial protein located on the outer
surface of mitochondria. Colca et al. described the identification of mitoNEET as a mitochondrial
target for the anti-diabetic drug pioglitazone11. By using a photo-affinity probe, they identified this
~17 kDa protein which carries a CDGSH domain. The mitoNEET was found to belong to a group
of zinc-finger proteins, although it contains two iron-sulfur clusters [2Fe-2S], instead of zinc12.
This protein is also present in several other species, including thermophiles13 as well as in plants14.
This suggests that mitoNEET belongs to an ancient family of proteins with an as yet unknown
function15. There are numerous presumed functions for mitoNEET in normal physiology and
pathophysiology, particularly in the central nervous system11. For example, it was shown that
downregulation of mitoNEET by microRNA-127 leads to inhibition of neurite outgrowth and can
induce neuronal cell apoptosis16. Recently, also it was shown that mitoNEET ligands such as
TT01001 may have neuroprotective activity in stroke17 which prompted the current study using
the mitoNEET ligand NL-1.
Our overarching goal is to develop mitoNEET ligands which can be used as clinical leads18, and
NL-1 represents a promising small molecule mitoNEET ligand which was derived from the parent
compound pioglitazone (Figure 1). We have previously shown that the mitoNEET ligand NL-1 is
neuroprotective in Parkinson’s disease model19, NL-1 can protect stem cells from
reperfusioninjury before being transplanted20 and mitigates tissue loss post traumatic brain injury
(TBI)21. These promising reports led us to explore the effect of NL-1 on mitochondrial function
in cells of the central nervous system. The work presented in this chapter investigates the role of
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NL-1 in mechanisms that improve cell survival and thus lays the foundational premise for its
possible use as a stroke therapeutic.
3.2. Materials and Methods
Materials
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. NL-1
was prepared as described previously22.
Methods
Experimental animals
All mice were housed in the vivarium facilities, and all experiments were done in accordance
with the West Virginia University Institutional Animal Care and Use Committees, and according
to the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the
U.S. National Institutes of Health. Male C57BL/6J mice (3-4 months) were used for the glucose
tolerance testing. Each group of mice were randomly assigned to each treatment group, with
number of animals 4-5 in each group.
PPAR-g binding test
PPAR- activation was determined using the IndigoBiosciencs PPAR- activity kit. The cells
containing a PPAR-g luciferase construct were reconstituted in the cell recovery medium and 100
μL of the reconstituted cell suspension was seeded into white 96 well plate. The plated cells were
treated with the positive control rosiglitazone (4 M) and the test compound NL-1 (10 M). The
plate was transferred to an incubator at 37°C for 24 hours. After 24 hours, the cell media was
aspirated and 100 μL of luciferase detection reagent was added to each well, allowing the plate to
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rest at room temperature for at least five minutes. The luciferase activity was measured by
quantifying the luminescence on a plate reader.
Glucose tolerance test
Glucose tolerance test (GTT) was performed in C57BL/6J mice by intraperitoneal injection of
glucose (1.5 g/kg of bodyweight) after overnight fasting. The mice were injected with either
DMSO as the vehicle control or 10 mg/kg NL-1, IP. Blood was collected from tail vein at the time
points of 30, 60, 90 and 120 minutes following glucose injection. The glucose levels were
measured using a OneTouch glucometer (LifeScan, Milipitas, CA).
Kinase Panel
NL-1 was screened against a panel of kinases from Reaction Biology at 10 µM
(www.reactionbiology.com). The panel included a set of 349 typical kinases, while 20 atypical
kinases were tested for inhibition. NL-1 was tested at 10 µM in DMSO, and the concentration of
ATP used for the kinase screen was 10 µM ATP. Staurosporine was used as positive control to
show expected inhibition of kinase assay.
Cell culture
N2A cells, a mouse neuroblastoma cell line, were obtained from ATCC (Manassas, VA). N2a
cells were used to determine the effect of NL-1 on cellular physiology in a neuronal cell line. The
cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (all from Thermo-Fisher Scientific, Pittsburgh PA), and cultured at 37°C
and 5% CO2. For the oxygen-glucose deprivation study, we followed our previously published
methods.
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Cell oxidative stress and mitochondrial membrane potential
To evaluate the effect of oxidative stress, N2A cells were treated with NL-1 in a dose-dependent
manner spanning a concentration range of 8 log units for 1 hour, followed by addition of Amplex
Red (Invitrogen) to all wells of the plate, and fluorescence recorded using a BioTek Cytation 3
(Winooski, VT) plate reader (540/590 Ex/Em) 25 minutes later.
Calcium flux assay
Calcium movement in N2A cells were determined using the Enzo FLUOFORTE calcium assay
kit, according to the manufactures instructions. Cells were prepared the day before and plated in
black 96-well plates at 10000 cells per well. The following day, the culture medium was removed
and the cells were treated with the non-fluorescent FLUOFORTE Dye-loading solution and
incubated for 45 min at 37⁰C after which the media was changed to HBSS buffer with calcium and
no phenol red. The cells were treated with DMSO as a control and NL-1 at 10 M. The effect on
calcium movement was expressed as relative fluorescence measured on a BioTek Synergy 4 plate
reader with Ex: 485 and Em: 528 at a kinetic setting. As control, calcium influx was stimulated by
depolarizing the cells with the addition of 50 mM KCl in HBSS23.
Electron Transport Chain Complex Activities
Electron transport chain (ETC) complexes I, IV, activities were measured spectrophotometrically
as previously described24. Briefly, brain was resected from mice. Mitochondria were isolated from
organs using BioVision Mammalian Mitochondria Isolation Kit for Tissue & Cultured Cells
(Catalog #: K288), resuspended in 1 mL KME buffer each, and stored at -80°C. Complex I (NADH
dehydrogenase) activity was determined by measuring NADH oxidation at 340nm. Complex IV
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(cytochrome c oxidase) activity was evaluated by measuring the oxidation of cytochrome c at 550
nm. Each treatment group was comprised of 8 replicate wells in a 96-well plate. Bradford assay
was used to measure protein concentration in isolated mitochondria from brain and liver that was
used when performing calculations to obtain measurements expressed as nanomoles substrate
converted/min/mg of protein. The mean measurement of each treatment group was compared with
the mean of the control group (DMSO-only) with a One-Way ANOVA using GraphPad Prism 8
software program following the exclusion of outliers as determined by ROUT (Q = 1%) outlier
method.
Effect of NL-1 on mitochondrial membrane potential
The effect of NL-1 on mitochondrial membrane potential was assessed using previously published
method25. Briefly, N2A cells were seeded into black 96 well plates. The next day, this was followed
by the addition of ursodeoxycholic acid (500 nM) as a positive control, and NL-1 at 10 µM for 30
minutes, followed by the addition of TMRM (10 nM final concentration) for an additional 10
minutes. Brilliant Black (1 mg/ml stock) was added the plates to quench background fluorescence.
The plate was read using a BioTek Cytation 3 plate reader at 540 nm excitation and 590 nm
emission wavelengths.
Effect of NL-1 on lipid peroxidation
The effect of NL-1 on lipid peroxidation was determined using the TBARS assay quantifying of
thiobarbituric acid derivatives (TBARS). Briefly, N2A cells were seeded in 6 well plates, at
500,000 cells per well, and were treated with NL-1 (10 M) and hydrogen peroxide H2O2 (100
M) for 24 hours. Cells were lysed with 200 L RIPA buffer and placed in 1.5 ml centrifuge tubes.
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The lysates were then treated with 200 µL of 10% trichloroacetic acid for 15 minutes on ice. After
centrifugation at 2000 x g, the supernatant was mixed 1:1 with 0.67% w/v thiobarbituric acid and
boiled for 10 min. Absorbance was measured at 532 nm using a BioTek multimodal plate reader.
Effect of NL-1 on cellular respiration
The Seahorse assay using the Seahorse XF96 (Agilent Technologies, Santa Clara, CA) was used
to assess the impact of NL-1 treatment on cellular respiration and glycolysis. N2a cells were seeded
into collagen-coated Seahorse 96-well XF Cell culture microplate at a density of 20000 cells per
well. Cells reached confluence after 24 hours and were then subjected to treatment with vehicle
control or 10 μM NL-1 for either 3 or 24 hours. The Seahorse XF96 measured oxygen consumption
rate (OCR) under different conditions using sequential addition of oligomycin, carbonyl cyanide
p-trifluoromethoxyphenylhydrazone (FCCP), antimycin A and rotenone. The assay provided
information about the parameters of mitochondrial respiration such as basal respiration, ATPlinked
respiration, proton link, maximal respiratory capacity, spare respiratory capacity and
nonmitochondrial respiration. The second measurement performed by Seahorse XF96 was that of
the extracellular acidification rate (ECAR), which is a measure of cellular glycolysis. The Seahorse
XF96 measured ECAR under different conditions using sequential addition of glucose, oligomycin
and 2-deoxyglucose. The assay provided information about the parameters such as glycolysis,
glycolytic capacity, glycolytic reserve and non-glycolytic acidification.
Oxygen glucose deprivation and reperfusion (OGDR)
An in vitro cerebral ischemia and reperfusion model was employed by exposing the cells to oxygen
and glucose deprivation (OGD). Cell culture medium was replaced with the glucose deficient
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Hank’s Balanced Salt Solution (HBSS), containing 10% FBS and transferred to the BioSpherix X3
Xvivo System hypoxia chamber, with 0.1-0.2% oxygen, 5% carbon dioxide. The temperature of
hypoxia chamber was maintained at 37°C. The cells were incubated in hypoxia chamber for 3
hours. After the desired period of hypoxia, the glucose-free medium was replaced with normal cell
growth medium and cells were incubated in normal growth environment for 24 hours, mimicking
the reperfusion following cerebral ischemia.
Effect of NL-1 on hydrogen peroxide generation following OGDR
The in vitro efficacy of NL-1 in reducing generation of ROS was studied using Amplex Red assay
(Thermo Scientific). N2a cells were plated in a black 96-well plate at a density of 10,000 cells per
well. After 24 hours, cells were subjected to OGD. The cells were treated with NL-1 drug during
the period of recovery. After the 24-hour recovery, 50 µL of Amplex Red working reagent was
added to each well and allowed to react in dark at room temperature for 30 minutes. The amount
of hydrogen peroxide in each well was measured by fluorimetry using the BioTek Synergy H1
plate reader (BioTek Instruments, Winooski, VT), at an excitation and emission wavelength of 530
nm and 590 nm, respectively. The data of each plate were normalized for the control wells of that
plate, and then compared with other plate replicates.
Statistical analysis
Data were analyzed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). Differences
between two or more groups were assessed using Student’s t-test and one-way ANOVA,
respectively. Data are expressed as mean ± standard error of the mean (SEM). Values of P < 0.05
were considered statistically significant in all experiments.
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3.3. Results
PPAR-γ binding analysis of NL-1
Figure 3.1 shows the results of luminescence intensities for vehicle, the positive control
rosiglitazone and the test compound NL-1. The luminescence intensity of rosiglitazone was found
to be significantly higher than that of the vehicle and NL-1. The luminescence intensity for vehicle
and NL-1 were comparable, and no statistically significant difference was seen between the two.
These results indicate that NL-1 (10 µM) did not activate PPAR- at the dose tested, as compared
to the positive control compound rosiglitazone (4 µM), which was able to activate PPAR- as
expected.
Effect of NL-1 on blood glucose levels
The ability of NL-1 to affect blood glucose levels was tested using an intraperitoneal glucose
tolerance test. Figure 3.2 shows a glucose concentration (mg/dL) versus time plot for vehicle and
NL-1 treated mice. The near overlay of the two plots showed that NL-1 did not have a significant
effect on altering blood glucose levels when dosed at 10 mg/kg. The AUC values for vehicle and
NL-1 treated groups were found to be 43860 ± 2155 mg/dL.min and 44120 ± 2820 mg/dL.min,
respectively.
NL-1 effect on kinases
To test the kinase inhibition of NL-1, we used a kinase panel consisting of wild type and atypical
kinases. The Reaction Biology panel used a radiometric assay which directly measures kinase
catalytic activity toward a specific substrate26. NL-1 did not appreciably inhibit kinases out of a
panel of 349 typical and 20 atypical kinases. Amongst the typical kinases, the results indicate
inhibition of the WNK family of kinases. These include WNK1 (76.44% of control), WNK2
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(66.89% of control) and WNK3 (54.75% of control), as shown in Figure 3.3(A). The results for
20 atypical kinases are expressed as the percent inhibition of control in Figure 3.3(B). Among the
atypical kinases, inhibition was observed for PDK2/PDHK2 (65.5% of control) and PDK3/PDHK3
(73.8% of control).
Calcium flux assay
The fluorescence intensity was measured as a function of calcium mobilization or flux for untreated
cells and cells treated with 10 μM NL-1, using the Enzo FLOUFORTE calcium assay kit. Figure
3.4(A) shows that the kinetic measurements performed over a period of 25 minutes indicated no
significant difference between the relative fluorescence intensities for control and
NL-1 treated cells, indicating that the baseline calcium uptake was unaffected by NL-1 treatment.
Similar effect was seen on cells that were stimulated by addition of 50 mM KCL (Figure 3.4B),
wherein NL-1 did not show significant effect on calcium flux at the dose tested.
Effect of NL-1 on electron transport chain complexes
We evaluated the effect of NL-1 treatment on mitochondrial function. NL-1 interactions with the
components of electron transport chain such as complex I (NADH dehydrogenase) and complex
IV (cytochrome c oxidase) were studied my measuring the concentrations of NADH and
cytochrome c, which are the substrates of these enzymes. At 10 M, NL-1 was found to
significantly increase Complex I (Figure 3.5A) function by about 33% of the DMSO control. At
the same concentration, NL-1 had no significant effect on the complex IV activity (Figure 3.5B).
Effect of NL-1 on mitochondrial membrane potential
Mitochondrial membrane potential was measured using the TMRM assay. TMRM (tetramethyl
rhodamine methyl ester) is a lipophilic cationic dye that is accumulated by the mitochondria in
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proportion to the membrane potential. It exhibits a red shift in fluorescence spectra upon
accumulation in the mitochondrial membrane due to a quenching in the fluorescence intensity27.
Ursodeoxycholic acid at 500 nM was used as a positive control. Figure 3.6 shows that the
fluorescence intensities of ursodeoxycholic acid and NL-1 were found to be significantly higher
than that of the vehicle treated cells. Thus, NL-1 was found to improve the mitochondrial
membrane potential at a concentration of 10 μM.
Effect of NL-1 on lipid peroxidation
The thiobarbituric acid reactive substances (TBARS) assay was used to determine the ability of
NL-1 to reduce lipid peroxidation. The lipid peroxidation products react with thiobarbituric acid
upon heating to yield a pink colored product that can be quantified using colorimetry28. N2A cells
were treated with H2O2 to induce lipid peroxidation, for a period of 24 hours. Figure 3.7 describes
the absorbance intensities for TBARS generated, which is used as index for lipid peroxidation, for
the four groups: control, H2O2 alone, H2O2 and NL-1, and NL-1 alone. Cells treated with H2O2 and
NL-1 (10 μM) significantly reduced the presence of the TBARS as compared to H2O2 alone.
Effect of NL-1 on mitochondrial respiration
The impact of NL-1 on mitochondrial respiration was studied using the Seahorse XF96 assay. The
data were obtained for mitochondrial respiration which is expressed as the OCR plotted as a
function of time and sequential addition of drugs that modulate respiration (Figure 3.8A and
3.8C). The OCR for different parameters of mitochondrial respiration obtained was plotted as a
comparison between DMSO control and 10 μM NL-1 (Figure 3.8B and 3.8D). For the acute
treatment period of 3 hours, NL-1 was found to significantly improve the maximal respiration and
spare respiratory capacity of N2a cells (Figure 3.8B). For a prolonged drug exposure of 24 hours,
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NL-1 treatment also significantly improved the cellular basal respiration along with the maximal
respiration and spare respiratory capacity (Figure 3.8D). Similarly, the ECAR was plotted as a
function of time and sequential addition of drugs that modulate glycolysis (Figure 3.9A and 3.9C).
The ECAR for glycolytic parameters obtained was plotted as a comparison between DMSO control
and 10 μM NL-1 (Figure 3.9B and 3.9D). NL-1 acute treatment (3 hours) had no significant
impact on the glycolysis in N2a cells, while prolonged exposure of 24 hours improved the cellular
glycolytic capacity.
Effect of NL-1 on hydrogen peroxide generation following OGDR
The efficacy of NL-1 in reducing peroxide generation was studied by subjecting N2a cells to OGD
conditions for a period of 3 hours, and a reperfusion period of 24 hours (Figure 3.10). The
hydrogen peroxide produced was measured using the Amplex Red assay, and each treatment was
compared to control. It was found that NL-1 had a significant effect in reducing the peroxide
produced at a dose of 10 and 30 µM, for an OGD period of 3 hours.
3.4. Discussion
The aim of this study was to perform preliminary investigation into the viability of the
mitoNEET ligand NL-1 as a possible therapeutic for ischemia and reperfusion injury. The protein
mitoNEET is a located on mitochondrial and has been suggested to regulate the bioenergetics of
mitochondria29. Here we evaluated the pharmacological properties of NL-1, a mitoNEET ligand
synthesized by our group22, on its ability to interact with the cellular mitochondrial system, and we
found that NL-1 can be used as a potential neuroprotective agent for mitigating the pathology of
cerebral ischemia and reperfusion injury18,30.
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MitoNEET belongs to the iron-sulfur protein family (gene: cisd), and contains 2Fe-2S
clusters, which have been reported to be redox active31. Low pH conditions, may lead to the cluster
ejection from the protein contributing to ferroptosis downstream. The natural endogenous ligand
of mitoNEET remains to be elucidated, but some studies have indicated that it may play a role in
glutathione mediated redox reactions32–34, as well as interacting with related metabolic systems
including adiponectin35 and GDH36. MitoNEET was first identified from the binding of
pioglitazone, a type II diabetic glitazone11. Certain actions of pioglitazone such as lowering of lipid
levels were independent of its known target, the PPARγ receptor. Investigation into its off-target
actions led to the discovery of the mitochondrial protein mitoNEET. Since pioglitazone has been
evaluated by others in brain related injuries, including reperfusion injury21, stroke37,38 and
traumatic brain injury (TBI), we were interested in using mitoNEET as a target to rescue cells
following ischemia and reperfusion injury by mitigating the effect of mediators of cell death
following stroke such as ROS and inflammatory markers. However, using a known glitazone drug
such as pioglitazone or rosiglitazone would not have been a rational approach for stroke therapy,
as the actions of these drugs on PPARγ receptor would lead to unwanted anti-diabetic effect. With
this premise, our group previously developed a mitoNEET ligand, NL-1, with conserved the
thiazolidinedione pharmacophore22. We aimed to use NL-1 to probe the biochemistry and
physiology of mitoNEET. We were interested in evaluating NL-1 for similar class profiling as
pioglitazone.
The first important step toward establishing NL-1 as a stroke therapeutic was to show that the
molecule was bereft of any PPARγ anti-diabetic effects seen from the glitazone drugs. To this
effect, we resorted to both, in vitro and in vivo testing. The in vitro assay was performed using a
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PPARγ binding kit which has been widely used to test for PPARγ agonists and antagonists39–41.
The kit contained proprietary cells transfected with a PPARγ-luciferase construct, which comprises
of a luciferase reporter gene functionally linked to a PPARγ responsive promoter. The
luminescence intensity of the luciferin substrate is directly proportional to the analyte binding to
the PPARγ receptor. The significantly higher luminescence intensity for the positive control
rosiglitazone compared to NL-1 and vehicle control helped establish that NL-1 was not a PPARγ
ligand. We confirmed that NL-1 did not have an anti-diabetic effect using an in vivo glucose
tolerance test in mice. Intraperitoneal glucose tolerance test is widely utilized to determine the
ability of test compounds to lower blood glucose levels42,43. The mice used for this study were
fasted overnight, which initiates a catabolic state in mice as they food consumption is primarily
nocturnal44. The concentration-time curves for both, vehicle and NL-1 treated mice nearly
overlapped. The similar AUC values for both groups indicated that NL-1 has no impact on
lowering of blood glucose levels. These results for NL-1 are in contrast to the published effects of
pioglitazone, a PPAR- agonist, which reduced serum glucose levels45.
Protein kinases are a vital category of enzymes as they play a central role in a host of cell
signaling pathways. They array of kinases present can serve as targets for different small
molecules, which could elicit unwanted effects. The affinity of NL-1 for kinases has been untested
and we intended to check for inhibition of kinases by NL-1. The high throughput kinase panel used
included members of all major human protein kinase families26. Staurosporine is a general kinase
inhibitor that is widely used as the positive control for a kinase panel46,47. The only kinase family
amongst the typical kinases inhibited by NL-1 was the WNK kinase family, particularly WNK3.
WNK kinases or With-No-Lysine kinases play an important role in body fluid and ion homeostasis
and regulates blood pressure48,49. An inhibitor of WNK kinase family, WNK463, was shown to
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lower mean arterial pressure, and increase urinary excretion of sodium and potassium50. It has been
recently reported that WNK3 is upregulated upon onset of intracerebral hemorrhage which in turn
deteriorates brain injury via the WNK3/SPAK/NKCC1 pathway51. WNK3 knockout in mouse and
rat models exhibit significantly reduced infarct volumes, cerebral edema, axonal demyelination,
BBB damage and improved neurocognitive behavior following an ischemic stroke51–53. Of note is
that fact that NL-1 was used at a single concentration of 10 μM, which is a high concentration for
kinase inhibition. A more detailed investigation at lower concentrations of NL-1 is necessary to
determine its effective inhibitory actions on WNKs and PDKs. Nonetheless, a possible inhibition
of WNK3 by NL-1 could contribute to improved outcomes after stroke, and presents a promising
mitoNEET-independent axis that warrants further investigation.
Calcium homeostasis plays an important role in neurodegeneration following ischemia and
reperfusion injury. Accumulation of intracellular calcium activates the mediators of apoptosis and
necrosis. In mitochondria, excess calcium leads to swelling and a loss of membrane potential which
increases the permeability of mitochondrial membranes, promoting cytochrome c
release54,55. It could also lead to loosening of BBB tight junctions, leading to increased
permeability56. Considering the importance of intracellular calcium in regulation of cell survival
after stroke, we performed the calcium flux assay to determine if NL-1 itself affected the calcium
levels in the cells. The FLUOFORTE assay kit by Enzo Life Sciences has been used to quantify
the intracellular calcium mobilization57. The assay utilizes a cell permeable fluorogenic calcium
binding dye, which upon hydrolyzed by intracellular esterases, gets converted to a cell
impermeable negatively charged form. The dye has a calcium-binding moiety which self-quenches
the fluorescence of the dye in absence of calcium. This quenching is relieved by binding of
calcium, and thus, the fluorescence signal is directly proportional to the amount of intracellular
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calcium. KCl was used to increase the extracellular potassium ion concentrations, which in turn
increases the influx of calcium ions through the voltage gated calcium channels23,58. This study
shows that NL-1 neither alters the intracellular calcium concentrations, nor does it prevent the
influx of calcium ions when the cells are depolarized with KCl. Thus, NL-1 does not affect the
calcium homeostasis in vitro.
Next, we decided to focus on the effect of NL-1 on mitochondrial bioenergetics, since the
drug target mitoNEET is a mitochondrial enzyme. We examined the electron transport chain
complex I and IV activities to see how NL-1 affected cellular respiration. Complex 1 or NADH
dehydrogenase activity was measured by spectrophotometry, which involves catalytic oxidation of
NADH to NAD+ with subsequent reduction of cytochrome c. Complex I activity has been
shown to be decreased following ischemia and is not restored upon reperfusion59,60. Improvement
in complex I activity contributed to a cerebral-protective effect in a mouse stroke model60–62, while
an impairment in complex I activity exacerbates stroke63. Thus, improvement in complex I activity
with NL-1 treatment bodes well for cell survival after ischemia. While ischemia is the primary
cause of hampered complex I activity, complex IV activity is mainly inhibited by a period of
prolonged reperfusion64. NL-1 caused no significant change in the complex IV activity. The results
possibly suggest that the protective actions of NL-1 on the respiratory could be predominantly seen
during the ischemic phase.
The mitochondrial membrane potential is the electrochemical gradient across the
mitochondrial inner membrane that is the driving force for the ATP generation process. In ischemia
and reperfusion injury, oxidative stress and calcium ion build-up can lead to a loss of membrane
potential which accelerates cellular apoptosis. We tried to determine if NL-1 had an effect in
altering the mitochondrial membrane potential using TMRM, a commonly used fluorimetric
56

assay65–67. TMRM can be used to measure mitochondrial potential in both, live cells as well as
isolated mitochondria. Its advantages include that it readily equilibrates in the mitochondria, shows
little membrane potential independent binding, does not inhibit the electron transport chain and
has low toxicity to the cells65,67. Ursodeoxycholic acid has been reported to improve mitochondrial
membrane potential, and hence was used as a positive control. The improvement in mitochondrial
membrane potential by NL-1 was comparable to ursodeoxycholic acid. Thus NL-1 could have a
positive impact on the membrane potential and could provide an impetus to ATP production68.
The mitoNEET has several lysine residues in its structure, and these lysine residues seem
to be susceptible to modification by the oxidative stress by-product of lipid peroxidation,
4hydoxynonenoal (4-HNE). Proteomics studies indicated that LYS55 is modified by 4-HNE, via
an aldehyde covalent bond69. Since we show that NL-1 reduces lipid peroxidation, we theorize that
NL-1 might be augmenting in part, the modification of this LYS55. Lipid peroxidation is a
consequence of oxidative stress and elevated levels of TBARS due to lipid peroxidation have been
reported in rats models as well as patients with ischemic stroke70,71. In a clinical trial for acute
ischemic stroke, glycine has been found to lower the levels of TBARS in CSF; one of the reasons
for its neuroprotective actions72. Although the effect observed was modest, the potential lowering
of TBARS by NL-1 could benefit in the mitigation of stroke pathology.
The Seahorse XF96 instrument effectively measures the two important components of ATP
production, glycolysis and mitochondrial respiration, within a 200 μm area in the vicinity of the
cells. The sensor sleeves that cover each well of a 96-well plate consists of two fluorophores, one
quenched by oxygen measuring the mitochondrial respiration and the second one that senses
protons and measures glycolysis73,74. The instrument has means to sequentially add compounds
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that modulate respiration and glycolysis. The instrument first measures the baseline respiration in
cells pre-treated with NL-1. Following the establishment of a baseline, complex V inhibitor
oligomycin is injected with blocks any ATP-linked respiration. ATP-linked respiration is obtained
by subtracting OCR pre and post oligomycin addition. The proton gradient can be calculated by
subtracting non-mitochondrial respiration from oligomycin OCR. Next, FCCP is added which
removes the inner mitochondrial membrane gradient such that the maximal respiratory capacity is
reached. Maximal respiratory capacity is calculated by subtracting non-mitochondrial respiration
from FCCP OCR. Mitochondrial reserve capacity can be calculated by subtracting basal respiration
from maximal respiration. The last addition consists of antimycin A (complex III inhibitor) and
rotenone (complex I inhibitor), which essentially stops the ETC functioning and shows the nonmitochondrial respiration. In a similar manner, glycolytic parameters can be determined by
sequential addition of compounds and measuring the ECAR. Upon the
establishment of the baseline ECAR, glucose is added, and the cells undertake glycolysis which is
denoted as the basal glycolysis. The next injection is of oligomycin which inhibits ATP synthase
(complex V) and shifts the energy production to glycolysis, to reveal the maximum glycolytic
capacity. Finally, 2-deoxyglucose which competes with glucose to bind glucose hexokinase is
added, thus inhibiting glycolysis and revealing the non-glycolytic acidification. The reserve
glycolytic capacity can be calculated by subtracting basal glycolysis rate from the maximal
glycolytic capacity. Our experiments reveal that NL-1 primarily helps to improve the
mitochondrial respiration, compared to glycolysis. These actions of NL-1 at the mitochondria seem
logical as the NL-1 target mitoNEET is a mitochondrial membrane protein. Further, it is possible
that the improvement in respiration brought about by NL-1 is a time dependent phenomenon, since
a prolonged 24-hour exposure was found to improve the basal respiration, which was not seen in
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cells treated for 3 hours. Overall, this experiment reveals a potential for NL-1 to improve
mitochondrial respiration and ATP production in cells that might suffer from a massive ATP deficit
following ischemia.
Finally, in order to establish NL-1 as a potential stroke therapeutic, we needed to investigate
the effect of NL-1 in mitigating at least one of the multiple axes that cause cell death in ischemia
and reperfusion injury. For this purpose, we developed an in vitro ischemia and reperfusion model
using mouse neuroblastoma (N2a) cells. HBSS supplemented with 10% FBS was used as the
glucose-free medium for cell incubation in the hypoxia chamber75,76. We studied the effect of NL1 on the levels of hydrogen peroxide, which is an important constituent of the ROS milieu.
Hydrogen peroxide is formed as a dismutation product of superoxide radical by mitochondrial
manganese superoxide dismutase enzyme77. It diffuses across the outer mitochondrial membrane
into the extra mitochondrial space, wherein it can be quantified78. We determined the effect of NL1 nanoparticles on peroxide generation using the sensitive fluorimetric Amplex Red assay79.
Amplex Red is a colorless substance that reacts with hydrogen peroxide in presence of horseradish
peroxidase in a 1:1 stoichiometry to yield a stable fluorescent compound
called resorufin80,81. The primary challenge with this assay involves prevention of light exposure
of Amplex red reagent for longer periods, and artificial generation of hydrogen peroxide by light
exposure of resorufin82,83. Our results showed that NL-1 had the ability to reduce peroxide
generation for a 3 hour ischemia period at a dose of 10 μM. Thus, NL-1 was found to have a
potential to address the elevated levels of ROS following stroke, which could aid in
neuroprotection.
In summary, this chapter describes the preliminary studies performed to investigate the
viability of using NL-1 as a stroke therapeutic. Our data indicate that the thiazolidinedione analog
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NL-1 is devoid of redundant anti-diabetic effects. Importantly, NL-1 acts on the mitochondrial
system to improve respiration, cell survival and lower ROS mediated adverse effects following
ischemia. This in vitro work lays the foundation for pursuing NL-1 as a potential stroke
therapeutic.
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Figure 3.1: The mitoNEET ligand NL-1 (10 µM) does not activate PPAR-gamma using a
reporter assay system. As a positive control rosiglitazone was used to activate PPAR-gamma (4
µM) with increased luciferase activity. NL-1 showed a statistically significant (P<0.05)
difference compared to vehicle control* and #compared to rosiglitazone. N = 4.
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Figure 3.2: Effect of an acute treatment of NL-1 on glucose levels in mice. NL-1 at 10 mg/kg
did not lower blood glucose after glucose tolerance test. Each data point represents mean + S.D.
where N = 4.

Figure 3.3: Testing for inhibitory effects of NL-1 using a kinase panel. (A) Typical kinase panel
shows that the only notable inhibition for the WNK kinase family, out of 349 kinases, and (B)
Atypical kinase panel showing significant inhibition of PDK2 and PDK3. Results are expressed as
the percent inhibition of control (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

Figure 3.4: NL-1 (10 M) effect on endogenous calcium and calcium influx in N2A cells.
Cells were treated with NL-1 for 15 minutes and the calcium flux measure with the Fluoforte
calcium kit. Control cells received DMSO only, with a final concentration of DSMO 1%. (A)
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Effect of NL-1 on baseline calcium uptake. (B) Effect of NL-1 on cells which have been stimulated
by KCl (50 mM) to stimulate voltage gated ion channels. The cells treated with NL-1 did not show
significant effects on calcium flux at the dose tested. Each data point represented by average +/S.D. were N = 3 -5 for each group. Abbreviation: relative fluorescent units (RFU).

Figure 3.5: Effect of NL-1 on mitochondrial complexes of the electron transport chain. A)
NL-1 (10 M) stimulates complex I activity in isolated mitochondria; B) NL-1 does not affect
complex IV in isolated mitochondria. Each bar represents average +/- S.D, where N = 3 (*p<0.05).
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Figure 3.6: NL-1 (10 M) stimulates mitochondrial membrane potential in N2A cells, with
ursodeoxycholic acid used as control (500 nM). Each bar represents average +/- S.D, where N = 3
(*p<0.05).

Figure 3.7: Lipid peroxidation assay (TBARS) show attenuation in N2A cells treated with
NL-1 (10 M). Cells were treated with hydrogen peroxide (100 M) for 24 hours. TBARS levels
were found to be significantly reduced for cells treated with NL-1 and hydrogen peroxide as
compared to hydrogen peroxide alone. Each bar represents average +/- SD were N = 3 (*p<0.05).
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Figure 3.8: Measurement of oxygen consumption rate (OCR) of N2a cells as a function of
mitochondrial respiration. The OCR is plotted over time with sequential addition of modulators
of respiration for (A) 3 hour and (C) 24 hour treatment. The OCR for parameters of mitochondrial
respiration are compared for control and 10 μM NL-1 for (B) 3 hour and (D) 24 hour treatment.
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Figure 3.9: Measurement of extracellular acidification rate (ECAR) of N2a cells as a function
of glycolysis. The ECAR is plotted over time with sequential addition of modulators of glycolysis
for (A) 3 hour and (C) 24 hour treatment. The ECAR for parameters of glycolysis are compared
for control and 10 μM NL-1 for (B) 3 hour and (D) 24 hour treatment.
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Figure 3.10: NL-1 protects neuronal cells against oxygen glucose deprivation and reperfusion
(OGDR). N2a cells were exposed to OGD conditions for 3 hours and reperfused for 24 hours. The
fluorescence intensity from Amplex Red assay is plotted as a percentage on control cells for a
series of NL-1 concentrations (*p<0.05).
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4.1. Introduction
Stroke is a leading cause of mortality and morbidity worldwide, with no proven therapies to
slow down the neuronal cell death after a stroke.1 About 80% of stroke cases consist of ischemic
stroke, wherein the blood supply to a brain region is impeded. As a result, the brain tissue is
deprived of vital nutrients such as oxygen and glucose. Unless the occlusion is removed and blood
supply is restored, prolonged deprivation of nutrients leads to formation of an infarct in the brain
tissue which is a result of cell damage to neurons, microglia, astrocytes and endothelial cells.
Multiple mechanisms of cell damage are activated following cerebral ischemia and reperfusion
which can be a function of location in the brain as well as the time elapsed since the onset of
ischemia. Although it might seem counterintuitive, restoration of blood supply, known as
reperfusion, can cause further damage. Effects of reperfusion, also known as reperfusion injury,
are the causative factors for cerebral edema and blood brain barrier (BBB) disruption2.
Energy failure is the immediate consequence of this ischemic event, as the brain cells are
unable to generate ATP molecules due to lack of glucose and oxygen. A decline in ATP generation
results in many downstream events such as the dysfunction of ATP pumps, loss of membrane
potential, prevention of neurotransmitter reuptake leading to excitotoxicity of neurotransmitters
such as glutamate. A direct effect of lack of impeded glucose and oxygen delivery is the alternation
of mitochondrial function. The mitochondria are involved in two important physiological functions
that include the generation of ATP and regulation of cellular apoptotic pathways. Oxidative stress
is a principle mechanism of cell damage following cerebral ischemia and reperfusion, mediated by
reactive oxygen species (ROS) such as superoxide radical, hydrogen peroxide, and the product of
nitric oxide and superoxide interaction: peroxynitrite. Ischemic events are known to activate
enzymes that produce ROS, which also see a surge in generation following reperfusion. These
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ROS can interact with matrix metalloproteases leading to BBB disruption, and also recruit
neutrophils and other leukocytes, adding an inflammatory dimension to the cellular damage3.
Mitochondria are the upstream regulators of the intrinsic pathway of neuronal cellular apoptosis,
with changes in the mitochondrial membrane integrity following ischemia and reperfusion injury
lead to the initiation of cellular apoptosis, resulting in eventual cell death.
MitoNEET is a protein present in the outer mitochondrial membrane, which was discovered
as an off-target binding site for the thiazolidinedione category of anti-diabetic drug pioglitazone4,5.
It is a 14 kD protein that exists as a homodimer. MitoNEET contains two ironsulfur clusters (2Fe2S) that are responsible for its physiological actions6,7. The iron-sulfur cluster is labile, and its
stability within the protein is dependent on its oxidation state8. It participates in redox processes
thereby regulating the bioenergetics of the cell, and can act as a sensor for ROS9. MitoNEET
interacts with endogenous molecules that are involved in cellular respiration10,11. MitoNEET has
been discovered to play a role in metabolic conditions, cancer as well as in neurodegenerative
diseases12,13. Loss of MitoNEET has been implicated to cause
neurodegeneration in Parkinson’s Disease and in spinal cord injury14,15. Pioglitazone, a mitoNEET
ligand has shown to have neuroprotective effects after spinal cord injury16. However, keeping in
mind about the anti-diabetic actions of pioglitazone, a mitoNEET specific ligand, NL-1, has been
previously developed in our lab17. NL-1 has been shown to reduce rotenone induced cell death,
and caused uncoupling of mitochondrial respiration. When tested with cardiac stem cells, it has
been found to improve their survival under an environment of oxidative stress18. With the current
background about mitoNEET and its ligand NL-1, we investigated the potential of NL-1 in
treatment of cerebral ischemia reperfusion injury, by targeting the mitochondrial pathways of cell
damage such as oxidative stress and apoptosis. The work presented involves development and
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characterization of polymeric nanoparticles for NL-1 delivery, and the in vitro efficacy testing.
Although this study focuses only on the in vitro efficacy of NL-1 nanoparticles, the long term aim
of this project is delivery of NL-1 to the brain for treatment of cerebral ischemia. This is the first
report of the formulation of NL-1, a first in class mitoNEET ligand into a nanoparticle drug
delivery system.
4.2. Materials and Methods
Materials
Acid end-capped PLGA Resomer RG 530H (50:50), amiloride hydrochloride hydrate,
chlorpromazine hydrochloride, genistein, and thiazolyl blue tetrazolium bromide (MTT) were
purchased from Sigma-Aldrich (St. Louis, MO). Polyvinyl alcohol was obtained from MP
Biochemicals (Solon, OH). Kolliphor P188 was a generous gift from BASF Chemicals Company
(Ludwigshafen, Germany). Rhodamine B was purchased from Fisher Chemicals (Fair Lawn, NJ).
Solvents such as dichloromethane, ethyl acetate, methanol and LC-MS grade acetonitrile were also
obtained from Fisher Chemicals. Triton-X 100 detergent was purchased from Acros Organics.
Βtubulin primary antibody for immunostaining was purchased from Abcam (ab15568).
AlexaFluor
488-conjugated Affinipure donkey anti-rabbit secondary antibody was purchased from Jackson
Immunoresearch Laboratories (West Grove, PA). Amplex Red Hydrogen Peroxide Kit was
purchased from Invitrogen (A22188) (Carlsbad, CA). FITC Annexin V Apoptosis Detection Kit
was obtained from BD Biosciences (catalog number: 556547) (Franklin Lane, NJ). The bEnd.3
cells and Dulbecco’s Modified Eagle’s Medium (DMEM) (catalog number 30-2002) were
purchased from American Type Cell Culture (ATCC, Manasas, VA). TrypLE Express and Fetal
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Bovine Serum (FBS) were purchased from Gibco.
Methods
Preparation of nanoparticles
PLGA nanoparticles loaded with NL-1 were prepared using emulsification and solvent evaporation
technique. Acid-end capped PLGA was dissolved (2% w/v) in organic phase consisting of
dichloromethane and ethyl acetate in a 1:1 ratio. This was emulsified with the aqueous phase
consisting of 1% w/v PVA and 0.5% w/v Kolliphor P188 as emulsifying agents. The primary
emulsion was achieved using ultrasonication process (Heat Systems Ultrasonics Inc., Model
W225). The nanoparticles were obtained after evaporation of the solvent by overnight stirring. The
nanoparticles were separated from the unentrapped drug using a 10 cm Sephadex G-50 column.
Finally, for long term storage, the nanoparticles were freeze dried using 5% mannitol as a
cryoprotectant. The blank nanoparticles were prepared using the same procedure without adding
NL-1 to the organic phase.
Characterization of PLGA nanoparticles
Both blank and NL-1 loaded nanoparticles were characterized for their particle size. The particle
size and polydispersity index analyses were carried out using the Malvern Zetasizer. The
nanoparticle samples were diluted 1:100, and each formulation was measured in triplicate. The
zeta potential of the nanoparticles was also measured using the Malvern Zetasizer. The particle
size of freeze-dried nanoparticles was measured by resuspending the nanoparticle powder in pure
water at a concentration of 1 mg/mL. The stability of resuspended nanoparticles was determined
by measuring the particle size of the suspension every week, for 60 days. Upon optimization of the
formulations, Scanning Electron Microscopy (SEM) was used to determine the particle
morphology as well as the size. The nanoparticle suspension was coated on a silica wafer and
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allowed to air dry. The dry film of nanoparticles was sputter coated with gold-palladium thin film
using Denton Desk V sputter coater (Denton Vacuun, Moorestown, NJ). Subsequently, the
particles were visualized using the Hitachi S4700 scanning electron microscope, at an operating
voltage of 5 KV.
The physical state of nanoparticles was assessed using X-ray diffraction (XRD) technique. Four
separate samples were analyzed that included the NL-1 drug in its pure form, blank PLGA
nanoparticles, NL-1 loaded PLGA nanoparticles and a physical mixture of NL-1 drug and NL-1
loaded PLGA nanoparticles. Powder X-ray diffraction measurement was performed at room
temperature using a PANalytical X’Pert Pro XRD equipped with Copper k-alpha 8047.2 eV X-ray
source.
A modified LC-MS/MS method for NL-1 quantification was developed based on a previously
described method19. The system comprised of ExionLC (SCIEX, Farmingham, MA) and an
ABSciEx QTrap 5500 mass spectrometer. A Phenomenex Luna Omega UPLC column (100 x 2.1
mm, 1.6 µM) was used to elute NL-1 with an isocratic flow of acetonitrile and water (85:15) at 0.3
mL/minute. NL-1 fragment at 263.1 Daltons was used for quantification.
The entrapment efficiency of NL-1 loaded PLGA nanoparticles was calculated by extracting the
drug from about 10 mg lyophilized nanoparticles. One milliliter acetonitrile was added to the
nanoparticles and subjected to ultrasonication for two minutes. The solution was then centrifuged
at 12,000 rpm for ten minutes and the supernatant was used to quantify NL-1 content. The percent
entrapment efficiency of NL-1 was calculated using the following formula:
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁 − 1
=

𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁 − 1 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
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In vitro release of NL-1
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The in vitro release of NL-1 from the lyophilized nanoparticles was studied using Slide-A-Lyzer
MINI Dialysis Units (Thermo Scientific, Waltham, MA), with a molecular weight cut-off of 3,500
Daltons. The release medium consisted of 20% v/v methanol in 0.1 M ammonium acetate buffer
pH 7.4. About 10 mg nanoparticles were weighed and dispersed in 600 µL of release medium. Five
hundred microliters of this suspension was packed in the dialysis units (donor compartment), and
the units were set afloat in 10 mL of release medium in a 50 mL tube (recipient compartment). The
tubes were incubated at 37 °C. For pure NL-1, an equivalent amount of NL-1 was prepared as a
dilution in the release medium, using a methanol stock solution (5 mg/mL) of the drug. Five
hundred microliters of the NL-1 dilution were added to the dialysis units, using the same set-up
used for NL-1 nanoparticles. At fixed time points, 500 µL of liquid was sampled from the recipient
compartments of both, pure NL-1 and NL-1 nanoparticles. An equivalent volume of release
medium was replaced to keep the volume constant. Sink conditions were maintained throughout
the release study. The sampled release medium was analyzed for NL-1 content using the
LCMS/MS method. The amount of NL-1 was plotted as percent cumulative released from the
nanoparticles versus time.
Nanoparticle uptake studies
The nanoparticle uptake study was performed in mouse endothelial bEnd.3 cells (ATCC,
Manassas, VA). Rhodamine labelled fluorescent nanoparticles were prepared using the
aforementioned procedure, with the addition of rhodamine B to aqueous phase prior to
ultrasonication. The nanoparticles were gel filtered to remove excess rhodamine, and were further
cleaned by centrifugation. The pellet obtained after second wash was used for uptake studies on
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the cells. This optimization to reduce background fluorescence was performed using Nanosight
NS300 (Malvern Panalytical) with a 532 nm laser, and 565 nm filter. For the uptake study, cells
were plated in 6-well plates at a seeding density of 150,000 cells per plate. Cells were incubated
with rhodamine nanoparticles dispersed in cell culture medium, for different time periods of 1, 3,
6, and 24 hours. Once the incubation time was complete, the cells were washed thrice with PBS,
trypsinized and collected in flow cytometry tubes. The cells were further washed and pelleted
thrice with PBS within the tubes, and fixed with 0.4% paraformaldehyde. The samples were
analyzed for rhodamine fluorescence by flow cytometry using the BD LSRFortessa 4 laser
analyzer (Becton, Dickinson and Company, Franklin Lanes, NJ). The data were analyzed using the
BD FACS Diva 8.0 software. To determine the effect of energy dependence of nanoparticle uptake,
one plate of cells was pre-incubated at 4°C for 1 hour, after which the cells were treated with
rhodamine nanoparticles at 4°C for a single time point of 6 hours. The rhodamine nanoparticle
uptake was analyzed using flow cytometry, following the same procedure. The mechanism of
nanoparticle uptake was studied using specific uptake mechanism inhibitors. These included
amiloride hydrochloride hydrate (100 µM) for phagocytosis, chlorpromazine hydrochloride (3
µM) for clathrin mediated endocytosis, and genistein (400 µM) for lipid raft/ caveolar mediated
endocytosis. The cells were pre-treated with the inhibitors separately for 1 hour, after which they
were treated with rhodamine nanoparticles for a single time period of 6 hours, and analyzed for
cellular uptake using flow cytometry.
Nanoparticle localization studies
Rhodamine nanoparticle localization was studied qualitatively by with immunohistochemistry.
bEnd.3 cells were plated on coverslips and incubated with rhodamine labelled nanoparticles for a
period of six hours. Upon completion of the incubation period, the cells were washed three times
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with PBS, fixed with 4% paraformaldehyde for 15 minutes, and permeabilized with 0.1%
TritonX100 for 10 minutes. Upon permeabilization, the cells were blocked with 10% v/v goat
serum in 5% w/v bovine serum albumin (BSA). Subsequently, the cells were incubated in β-tubulin
primary antibody (Abcam ab15568) overnight at 4°C. Alexa Fluor 488-conjugated AffiniPure
donkey antirabbit IgG (Jackson Immuno Research Laboratories, West Grove, PA) was used as the
secondary antibody in 5% BSA for two hours at room temperature. Finally, the cell nuclei were
stained with DAPI (Thermo Scientific) for ten minutes, prior to mounting the coverslips on to
slides. Cells were washed thrice with PBS between each step. The cells were imaged using Nikon
A1R/SIM confocal and super resolution imaging microscope (Nikon, Tokyo, Japan).
In vitro ischemia model
The efficacy of NL-1 loaded nanoparticles to achieve neuroprotection following stroke was
determined as a function of their ability to reduce generation of hydrogen peroxide and occurrence
of apoptosis. An in vitro cerebral ischemia and reperfusion model was employed by exposing the
cells to Oxygen and Glucose Deprivation (OGD). The process involved removal of regular cell
culture medium and replacing the medium with the glucose deficient Hank’s Balanced Salt
Solution (HBSS), containing 10% FBS. The cell plates were then transferred to the BioSpherix X3
Xvivo System hypoxia chamber, with 0.1-0.2% oxygen, 5% carbon dioxide with nitrogen making
up the rest of gaseous flow. The temperature of hypoxia chamber was maintained at 37°C. The
cells were incubated in hypoxia chamber for a specific time period of either 3 or 6 hours. After the
desired period of hypoxia, the glucose-free medium was replaced with normal cell growth medium
and cells were incubated in normal growth environment for 24 hours, mimicking the reperfusion
following cerebral ischemia.
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Effect of NL-1 nanoparticles on hydrogen peroxide generation following OGD
The in vitro efficacy of NL-1 nanoparticles in reducing generation of ROS was studied using
Amplex Red assay (Thermo Scientific). bEnd.3 cells were plated in a black 96-well plate at a
density of 10,000 cells per well. After 24 hours, cells were subjected to OGD. The cells were
treated with NL-1 drug and an equivalent dose of NL-1 nanoparticles during the period of recovery.
After the 24-hour recovery, 50 µL of Amplex Red working reagent was added to each well and
allowed to react in dark at room temperature for 30 minutes. The amount of hydrogen peroxide in
each well was measured by fluorimetry using the BioTek Synergy H1 plate reader (BioTek
Instruments, Winooski, VT), at an excitation and emission wavelength of 530 nm and 590 nm,
respectively. The data of each plate was normalized for the control wells of that plate, and then
compared with other plate replicates.
Effect of NL-1 nanoparticles on cellular apoptosis following OGD
The ability of NL-1 nanoparticles to reduce apoptosis and enhance cell survival was determined in
bEnd.3 cells using the Annexin V assay. Cells were plated in 6-well plates at a seeding density of
150,000 cells per well. After approximately 24 hours, cells were subjected to OGD, and allowed
to recover with concurrent drug and nanoparticle treatments. 1 µM and 10 µM were the two
concentrations of NL-1 and an equivalent dose of nanoparticles tested. After about 24 hours, cells
were stained with Annexin V-FITC and propidium iodide, following which, they were sorted into
live, early apoptotic, late apoptotic and necrotic populations using BD LSRFortessa analyzer, and
analyzed using the BD FACS Diva 8.0 software. The cytoprotective ability of NL-1 nanoparticles
was determined as a function of percentage of live cells present.
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Toxicity studies on PLGA nanoparticles
The cytotoxicity of blank and NL-1 loaded PLGA nanoparticles was tested on hepatic HepG2 cells,
using the MTT assay. Cells were plated in clear 96-well plates at a seeding density of 10,000 cells
per well. The cells were treated with blank nanoparticle suspensions over a range of concentrations.
A highest concentration of 10 mg/mL freeze dried nanoparticles was used for treatment. The cells
were allowed to grow for 72 hours after treatments. Upon completion of the treatment incubation
period, 50 µL of 1 mg/mL MTT solution was added to each well and the plates were incubated for
two hours. After two hours, the MTT and media mix was aspirated, and the formazan crystals were
dissolved in DMSO at 37°C, for one hour on a shaker at 150 rpm (Benchmark Incu-shaker mini).
The analysis was carried out by measuring the absorbance at 570 nm using the BioTek Synergy
H1 plate reader (BioTek Instruments, Winooski, VT). All treatments were performed in triplicates.
Hemolysis studies on PLGA nanoparticles were performed based on a previously used method20,
using mouse blood. The blood was centrifuged to remove plasma and serum. The blood was
subsequently washed thrice with 0.9% normal saline, and the volume was made up to original
volume after the third wash. The blood solution was further diluted 1:10 in normal saline for the
assay. An approximate dose of 5 mg/kg for a mouse was calculated, and the required amount of
freeze dried nanoparticles were weighed and resuspended in 0.9% normal saline. Following
treatments were used: blank nanoparticles, NL-1 loaded nanoparticles, 10 µM NL-1 drug, negative
control (0.9% normal saline), and positive control (1% Triton X-100). One hundred microliters of
the treatment solutions were diluted with 700 µL 0.9% normal saline, to which 200 µL of blood
cells were added. The tubes were incubated at 37°C for 1 hour. After incubation, the tubes were
centrifuged, and the supernatant was used for analysis. The sample absorbance was measured at
405 nm and the percent hemolysis was calculated using the following formula:
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Statistical analysis:

Statistical analysis of data obtained was carried out by GraphPad Prism 7.04 (GraphPad Software,
CA) using one-way ANOVA followed by Dunnett’s post hoc test for comparison of multiple
groups. The graphs were prepared using GraphPad Prism 7.04. Data are presented as mean with
standard deviations. A statistically significant difference between groups was considered if the p
value was <0.05.
4.3. Results
Preparation and characterization of NL-1 loaded PLGA nanoparticles
The nanosuspension and the freeze-dried nanoparticles were characterized for their particle size
and zeta potential. The particle size of blank and NL-1 loaded nanoparticles was found to be 121.9
± 20.6 nm (n=5) and 123.9 ± 17.1 nm (n=12), respectively. The polydispersity index (PDI) of blank
nanoparticles was found to be 0.17 ± 0.09, whereas the NL-1 loaded nanoparticles have a greater
PDI of 0.27 ± 0.08. The particle size of freeze-dried nanoparticles upon resuspension was found
to have increased to 175.6 ± 6.8 nm (n=12), while the PDI was found to be 0.10 ± 0.02. The zeta
potential of blank and NL-1 loaded nanoparticles was found to be -16.8 ± 5.8 m V (n=3) and -26.2
± 1.3 mV (n=3), respectively. The results for particle size and zeta potential results are summarized
in Table 4.1. The freeze-dried nanoparticles in suspension were found to maintain their particle
size in the range of 168-180 nm over a period of 60 days (data not shown). SEM imaging showed
a spherical morphology for blank and NL-1 loaded nanoparticles. Figure 4.1 shows the SEM
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images for blank and NL-1 loaded nanoparticles. Scanning electron microscopy confirmed the
particle sizing results, as the nanoparticles were found to be in the general size range of 100 nm.
The LC-MS/MS method for analysis of NL-1 was successfully modified and used for studying the
entrapment efficiency of NL-1 and the in vitro release. The entrapment efficiency of NL-1 in the
current PLGA formulation was found to be 59.7 ± 10.1 %. To determine the physical state of NL1
in the nanoparticles, X-ray diffraction was performed on NL-1 drug, blank nanoparticles, NL-1
loaded nanoparticles, and a physical mixture of NL-1 drug and blank nanoparticles, as shown in
Figure 4.2. NL-1 drug was found to show a very specific X-ray diffraction pattern, with multiple
sharp peaks. The patterns of blank and NL-1 loaded nanoparticles were found to almost coincide,
showing that these have similar physical character. The pattern obtained for physical mixture of
NL-1 drug and blank nanoparticles showed an intermediate pattern. The NL-1 peaks were clearly
seen, along with the peaks seen with the nanoparticle only samples, albeit of lesser intensity.
In vitro release of NL-1 from nanoparticles
The in vitro release of NL-1 and NL-1 from the PLGA nanoparticles was plotted as cumulative
percent release as a function of time, shown in Figure 4.3. It was seen that NL-1 drug and NL-1
nanoparticles had a 78.7 ± 21.6% and 79.1 ± 7.2% drug release after a time period of 24 hours,
respectively. NL-1 drug was found to have a faster diffusion as compared to the release of NL-1
from formulation up to a 12-hour period. NL-1 and NL-1 nanoparticles have a 50% release at about
4 and 14 hours, respectively. The in vitro release studies demonstrate that the PLGA nanoparticles
have a slower release of NL-1 as compared to the pure NL-1 drug. The release is slower during
the phase between 6-20 hours. The nanoparticles do not sustain the release of NL-1, as the eventual
plateau phase of release is reached almost concurrently for both, the pure drug and the
nanoparticles, at 48 hours.
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Cellular uptake of nanoparticles
The time-dependent uptake of rhodamine nanoparticles in bEnd.3 cells was analyzed using flow
cytometry analysis. Figure 4.4 shows an overlay for the representative flow cytometry histograms
for each time point, along with the uptake quantification. Two negative controls, untreated cells
and cells treated with blank nanoparticles showed low fluorescence intensities as seen in the
histograms. The positive control of rhodamine nanoparticles had high fluorescence intensity,
indicated with a right shift in the histogram (data not shown). The rhodamine nanoparticle treated
cells showed a marginal shift beyond the threshold value. Upon quantification, it was found that
1-hour incubation showed a significantly higher rhodamine fluorescence as compared to the
negative controls. The uptake was found to be significantly higher at 3 hours as compared to 1
hour. However, after 3 hours the uptake showed a plateauing as there was no statistically
significant difference in fluorescence intensities at 3, 6 and 24 hours. We tested the energy
dependence of rhodamine nanoparticle uptake by comparing uptake at 37°C to that of 4°C (Figure
4.5). Compared to the nanoparticle uptake at 37°C, the uptake was significantly lowered during
treatment at 4°C, as seen from the left shift in the fluorescence histogram. The fluorescence
intensity at 4°C was similar to the negative control with no significant difference between the two.
We further tried to delineate the mechanism of nanoparticle uptake by treating cells with specific
uptake inhibitors, such as amiloride hydrochloride hydrate for phagocytosis, chlorpromazine
hydrochloride for receptor mediated endocytosis, and genistein for caveolar mediated endocytosis.
The uptake was quantified by measuring the rhodamine fluorescence by flow cytometry (Figure
4.6). The caveolar endocytosis inhibitor genistein was found to significantly reduce the uptake of
rhodamine nanoparticles into bEnd.3 cells to 61.8% as compared to the uptake into untreated cells.
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Amiloride HCl and Chlorpromazine HCl which inhibit phagocytosis and clathrin mediated
endocytosis, respectively, were found to have no significant effect on rhodamine nanoparticle
uptake.
Cellular localization of nanoparticles
The cellular localization studies were performed using fluorescent rhodamine nanoparticles as seen
in Figure 4.7. Confocal microscopy was used to image the nanoparticles in bEnd.3 cells that were
immune stained for β-tubulin (green) and nucleus was stained with DAPI (blue). The images are
shown as individual channels of DAPI for nucleus, FITC for β-tubulin and red for rhodamine. The
merged image shows localization of nanoparticles in the cytoplasmic region of the cells, within the
tubulin cytoskeleton. The second panel (Figure 4.7, E-H) shows the z-stack images of cells, which
confirm the presence of rhodamine nanoparticles in the cytoplasm of the cells. Figure 4.7I shows
a super resolution image, with nanoparticle localization in the cytoplasm.
NL-1 nanoparticles reduce hydrogen peroxide generation
The efficacy of NL-1 nanoparticles in reducing ROS generation was studied by subjecting bEnd.3
cells to OGD conditions for a period of 3 or 6 hours, and a reperfusion period of 24 hours (Figure
4.8). The hydrogen peroxide produced was measured using the Amplex Red assay, and each
treatment was compared to control. It was found that the NL-1 nanoparticles had a significant
effect in reducing the peroxide produced at a NL-1 dose of 2.5 µM, for a stroke period of 3 hours.
However, the efficacy of NL-1 nanoparticles was seen to decrease for a stroke period of 6 hours,
as significant reduction in peroxide levels was only seen at 10 µM and 20 µM NL-1 dose. Figures
4.8C and 4.8D compare the effect of nanoparticles against that of pure NL-1 drug. For 3 hour
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OGDR, NL-1 loaded nanoparticles were found to be more efficacious as compared to NL-1 drug,
while such an effect was not seen at 6-hour ischemia period.
NL-1 nanoparticles improve cell survival and reduce apoptosis
The cells were exposed to either 3 or 6 hours of ischemia, with subsequent treatment with 1 µM
and 10 µM of NL-1 and equivalent dose of NL-1 nanoparticles. The cells were differentiated into
four categories based on their staining. The live cells are unstained, the cells in early apoptosis
pick up a stronger signal of Annexin V-FITC, while the cells in late apoptosis and necrotic phase
have a strong PI signal. The results are expressed as percent survival of cells and percent of cells
in late apoptotic phase. Figure 4.9 A-D are representative images showing flow cytometry data,
and quantified in Figure 4.9 E-H. The cells undergoing apoptosis were predominantly found to be
in the late apoptotic stage. The cell survival for control for 3-hour ischemia was found to be 44.4
± 2.8%. NL-1 drug improved cells survival to 58.3 ± 2.3% at a concentration of 10 µM, however
no significant improvement in cell survival was seen at 1 µM concentration. In contrast, the
equivalent dose of nanoparticles significantly improved cell survival at both 1 µM (57.5 ± 3.0%)
and 10 µM dose (65.7 ± 0.2 %). Correspondingly, there was a decrease in the percent of cells in
late apoptosis for 10 µM NL-1, 1 µM NL-1 nanoparticles and 10 µM NL-1 nanoparticles. The NL1 nanoparticles showed a significantly higher efficacy as compared to the corresponding
concentration of NL-1 drug. For an ischemic period of 6 hours, the control showed a survival of
40.4 ± 1.1%. NL-1 drug showed improved cell survival at both 1 µM (56.2 ± 1.4%) and 10 µM
(71.0 ± 1.4%). Enhanced cell survival was also seen for NL-1 nanoparticles at 1 µM (57.3 ± 2.3%)
and 10 µM (69.8 ± 4.3%) concentrations. A corresponding significant decrease was seen in the
percentage of cells in late apoptosis for all treatments. However, there was no significant difference
in the efficacy of NL-1 nanoparticles and the NL-1 drug for the 6-hour ischemic period.
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NL-1 nanoparticle formulation was non-toxic
The inherent toxicity of blank and NL-1 loaded PLGA nanoparticles was studied using MTT
cytotoxicity assay on hepatic HepG2 cells (Figure 4.10A). A wide concentration range of blank
nanoparticles was used for the assay, with the highest concentration of 10 mg/mL. HepG2 cell
survival was found to be about 95.9 ± 5.6% at a nanoparticle concentration of 1 mg/mL and was
found to reduce to 68.2 ± 2.5% at the highest treatment concentration of 10 mg/mL, in blank PLGA
nanoparticles. For NL-1 loaded nanoparticles, the cell survival was found to be 80.4 ± 11.4%, and
58.1 ± 7.8% at 1 mg/mL and 10 mg/mL, respectively. The second toxicity parameter that was
investigated was the potential of PLGA nanoparticles to cause hemolysis of erythrocytes, since the
nanoparticles are intended for intravenous administration (Figure 4.10B). The positive control of
1% v/v Triton X-100 NL-1 showed 100% hemolysis. The NL-1 drug was found to have a slightly
higher hemolysis as compared to blank and NL-1 loaded nanoparticles, which showed an almost
zero percent hemolysis. The results obtained show that neither the blank nor the NL-1 loaded
nanoparticles showed any hemolytic activity.
4.4. Discussion
The goal of the current study was to formulate the mitoNEET ligand, NL-1, into a
nanoparticle dosage form, for use in ischemia reperfusion injury. Targeting mitochondrial
dysfunction post-stroke is an attractive drug target, as both neuronal cells and blood—brain barrier
endothelium cells are affected with ischemia reperfusion injury. Here we were able to develop
formulation strategy for NL-1, with an optimized activity profile in contrast to the drug alone.
The blank and NL-1 loaded PLGA nanoparticles were prepared successfully using
emulsification and solvent evaporation technique. The formulation employed acid end capped
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PLGA, a biodegradable polymer, which hydrolyzes into the inert lactic acid and glycolic acid
residues21. Emulsification and solvent evaporation is a commonly used technique for the
preparation of PLGA nanoparticles. The polymer is dissolved in organic solvent that is present as
globules in the continuous aqueous phase, stabilized on the interface by the surfactants (PVA and
Kolliphor P188). During solvent evaporation, the solvent diffuses into the continuous external
phase, causing the formation of nanoparticles upon aggregation and desolvation of the globules22.
Formulation parameters such as solvent, surfactants and their concentrations, polymer
concentrations were studied to arrive at the final formulation. The choice of solvent used to
dissolve polymer can be critical, as the nanoparticle size is a function of solvent diffusion out of
the droplets during evaporation23. Dichloromethane, ethyl acetate and acetone were tried as
solvents alone and in combination. Surfactants align at the organic-aqueous interface and stabilize
the system by reducing the interfacial tension24. Thus, the use of an ideal surfactant would dictate
the stability of the formulation. Non-ionic surfactants such as PVA, Kolliphor P188, and Kolliphor
P407 were tried at concentrations of 0.5% w/v and 1% w/v, as well as in combinations. The
surfactant combination yielding the most stable formulation, without affecting the particle size
range was found to be 1% w/v PVA and 0.5% w/v Kolliphor P188. Finally, the concentration of
PLGA to be used (2% w/v) was decided based upon the gradual increase in particle size observed
with increasing PLGA concentration. Higher aggregation observed at PLGA concentrations above
3% w/v made it imperative to limit the PLGA concentrations at 2%. Size exclusion
chromatography is a frequently used technique for the separation of the unentrapped drug from the
obtained nanoparticles25–27. The free NL-1 was separated from the PLGA nanoparticles using the
Sephadex G-50 column for size exclusion. PLGA nanoparticles in aqueous solution could be
vulnerable to hydrolytic cleavage, resulting in instability of the nanoparticles. Hence, the
formulation was freeze dried for long-term storage. The use of a cryoprotectant such as mannitol
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during freeze drying was warranted in order to prevent physical damage to the nanoparticles due
to mechanical stress of freezing and dehydration28,29. The use of cryoprotectant also allows for
rapid redispersion of the nanoparticles back into an aqueous solution28. The NL-1 nanoparticles
are intended for delivery to treat ischemic stroke in the long term, which would require them to
traverse the blood brain barrier (BBB). A nanoparticle size of under 200 nm has been found to be
desirable for effective treatment of diseases of the CNS30–32. The particle size of NL-1 loaded
PLGA nanoparticles in suspension as well as upon redispersion was found to be under 200 nm.
The zeta potential of the nanoparticles was found to be in the moderately negative range (anionic).
This was expected due to the use of acid-end capped PLGA during nanoparticle synthesis. For the
purposes of formulation stability, a zeta potential further away from the neutral range is preferred,
as repulsion between similarly charged particles is likely to prevent their aggregation. Nanoparticle
surface charge has been found to have an impact on the BBB and their brain uptake as well. A low
concentration anionic nanoparticles were found to be non-toxic to the BBB, and also showed a
higher brain uptake33. This formulation thus has a potential for efficient delivery of NL-1 to the
ischemic region in the brain, and at the same time not have a global BBB disruptive effect.
These results indicate that NL-1 is present in a different physical state in the nanoparticles,
in contrast to its native crystalline form, and there is a definite reduction in crystallinity of the drug.
The physical state of drug can impact the release of the drug from the nanoparticles, with crystalline
form offering impedance34. The presence of NL-1 in a non-crystalline form (amorphous or
dissolved) could lead to an efficient drug release. The nanoparticles do not sustain the release of
NL-1, as the eventual plateau phase of release is reached almost concurrently for both, the pure
drug and the nanoparticles, at 48 hours. The non-sustained release of NL-1 could be required, since
neurodegeneration following stroke is a time dependent phenomenon. A successful rescue of
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greater percentage of cells would require a quicker drug treatment. The release models that showed
the best fit include Korsmeyer-Peppas (R2: 0.9933), and first order release model (R2: 0.9812).
The R2 values obtained for the other models are summarized in table 4.2. The exponent for
Korsmeyer-Peppas fit was found to be 0.768. The Korsmeyer-Peppas model of drug release is used
for the first 60% of the release data, and can be helpful in determining the mechanism of drug
release35,36. The exponent of 0.768 in the Korsmeyer-Peppas fit of the release kinetics points
toward non-Fickian or anomalous release being the primary release mechanism of NL-1. The
release of NL-1 from PLGA nanoparticles is a possible combination of NL-1 diffusion and PLGA
erosion. A drawback of Korsmeyer-Peppas release model is that fact that it is used only for first
60% of the drug released. When the entire release data was fit to a model, it was found to be close
to first-order model. First order kinetics imply that the release of drug from the nanoparticles is
dependent on the concentration of the drug present in the system.
The first step toward effective treatment of cells by nanoparticles would require uptake of
the nanoparticles by the cells. Rhodamine nanoparticles were prepared and characterized for
particle size under a fluorescent filter on the Nanosight (data not shown). This was useful in
optimizing the wash-outs needed for the nanoparticles to eliminate background fluorescence, and
to confirm the presence of fluorescent nanoparticles. The studies were performed in bEnd.3
endothelial cells, a commonly used model for in vitro stroke studies37–39. The time-dependent
uptake of rhodamine nanoparticles in bEnd.3 cells was analyzed using flow cytometry analysis.
The significantly higher uptake after 1 hour could possibly be beneficial for cell rescue, which can
be a time sensitive phenomenon. The significantly lowered nanoparticle uptake at 4°C could
suggest that the functioning of proteins and enzymes involved in endocytosis is inhibited at lower
temperatures and is an energy-dependent active process.
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We further tried to delineate the

mechanism of nanoparticle uptake by treating cells with specific uptake inhibitors, such as
amiloride hydrochloride hydrate for phagocytosis, chlorpromazine hydrochloride for receptor
mediated endocytosis, and genistein for caveolar mediated endocytosis. The uptake was quantified
by measuring the rhodamine fluorescence by flow cytometry (Figure 4.6). The most prominent
mechanisms of nanoparticle uptake into cells include phagocytosis, clathrin mediated endocytosis,
and caveolar/lipid raft endocytosis. Phagocytosis is an actin-dependent uptake mechanism, which
is generally mediated by specialized cells such as macrophages, suitable to particles around 500
nm in size40. Clathrin mediated endocytosis involves binding of cargo (nanoparticles) to specific
receptors on the cell surface, leading to downstream recruitment of proteins that help internalize
the nanoparticles into a ‘coated pits’41. Caveolar endocytosis is mediated by components of lipid
rafts and occurs in cholesterol rich regions of the plasma membrane. These are vesicles formed by
cell membrane invaginations42. Each of the above mechanism was individually inhibited by using
specific inhibitors. A single concentration of inhibitors was used for each mechanism, based on
literature41–43. Lipid raft or caveolar mediated endocytosis was thus found to be the prominent
mode of nanoparticle uptake. Genistein is an inhibitor of receptor associated tyrosine kinases,
involved in the caveolar uptake mechanism44. The caveolar invaginations can be in the size range
of 50-200 nm, which would explain the endocytosis of these nanoparticles through this mechanism.
Moreover, nanoparticles with an anionic surface charge are known to interact with the cationic
lipid components of the lipid rafts in the cell membrane which further explains the mechanism
used by the nanoparticles for their uptake45. Upon their uptake, it is important that the nanoparticles
localize around the site of action of the drug they intend to deliver. The advantage of using confocal
microscopy was the ability to image z-stacks, which provides a better understanding of the position
of the nanoparticles within the cell, as compared to a twodimensional image. Cytoplasmic
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localization of nanoparticles is necessary for the activity of NL1 as a mitoNEET ligand. MitoNEET
is present in the outer mitochondrial membrane, and is oriented toward the cytoplasm46.
The efficacy studies for NL-1 loaded PLGA nanoparticles were performed using the in
vitro OGD model to mimic stroke. The studies were performed in bEnd.3 endothelial cells, a
commonly used model for in vitro stroke studies37–39. HBSS supplemented with 10% FBS was
used as the glucose-free medium for cell incubation in the hypoxia chamber47,48. Cellular toxicity
following ischemic stroke is multimodal, mediated via multiple mechanisms. Cell damage due to
generation of ROS and induction of apoptosis cascade are two of the primary causes of
cytotoxicity. Both of these mechanisms are mitochondrial in origin and relevant sites of
intervention for NL-1, since it binds the mitochondrial protein mitoNEET. We investigated the
effect of NL-1 nanoparticle treatment on both of these physiologic events.
An important ROS mediator generated in mitochondria is the superoxide radical. However,
measurement of superoxide produced in the mitochondria can be challenging due to the inability
of probes to permeate the outer mitochondrial membrane. Hydrogen peroxide is formed as a
dismutation product of superoxide radical by mitochondrial manganese superoxide dismutase
enzyme49. It diffuses across the outer mitochondrial membrane into the extra mitochondrial space,
wherein it can be quantified50. We determined the effect of NL-1 nanoparticles on peroxide
generation using the sensitive fluorimetric Amplex Red assay51. Amplex Red is a colorless
substance that reacts with hydrogen peroxide in presence of horseradish peroxidase in a 1:1
stoichiometry to yield a stable fluorescent compound called resorufin52,53. The primary challenge
with this assay involves prevention of light exposure of Amplex red reagent for longer periods,
and artificial generation of hydrogen peroxide by light exposure of resorufin54,55. The results
indicate that NL-1 nanoparticles are more effective at the shorter ischemic period of 3 hours as
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seen from the dose response of NL-1 nanoparticles in reducing the peroxide generation. A possible
explanation for this could be that other mechanisms of cell damage might predominate for a longer
duration of ischemia. ROS generation could likely be the predominant mode of cell toxicity at the
shorter ischemic period. Cell damage due to ROS has been implicated in the earlier time period of
ischemia56. We also compared the NL-1 nanoparticles to pure NL-1 drug in their ability to reduce
the peroxide generation. NL-1 nanoparticles had a greater efficacy as compared to NL-1 drug
during the shorter ischemia period. However, this effect was not seen for 6-hour ischemia period.
The second mechanism of cell death that has a mitochondrial dimension is apoptosis. The
ability of NL-1 nanoparticles in checking apoptosis and in turn improving the cell survival was
determined with the Annexin V apoptosis assay, which is commonly employed to detect apoptotic
and necrotic cell populations57,58. We found higher protective activity of the NL-1 nanoparticles as
compared to NL-1 drug-alone at the 3-hour ischemia period, however these results are not seen at
the longer ischemia duration of 6 hours. Although the NL-1 nanoparticles showed a greater cell
survival at both concentrations, the drug by itself was not effective at 1 µM for 3 hour ischemia
period. Apoptosis in cerebral ischemia has previously been described to be a biphasic event, in
which the apoptosis mediated by mitochondria occurs at a later stage59. It can be speculated that
improved activity of NL-1 for longer ischemia period is a possible result of increased
mitochondrial involvement in the apoptotic mechanisms. Further studies are needed to confirm this
hypothesis. Overall, the system helped reduce apoptotic populations of bEnd.3 cells.
The inherent toxicity of blank and NL-1 loaded PLGA nanoparticles was studied using
MTT cytotoxicity assay on hepatic HepG2 cells. Since liver is a primary metabolic organ, we chose
to perform this test on liver cells. The survival curve shows that even the highest concentration of
both, blank and NL-1-loaded PLGA nanoparticles did not induce a 50% cell death, and an IC50
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value could not be established. The concentration of 10 mg/mL was at least five times higher than
the highest concentration of nanoparticles used for efficacy studies. This is indicative that the
results obtained were not affected by any inherent nanoparticle toxicity. The second toxicity
parameter that was investigated was the potential of PLGA nanoparticles to cause hemolysis of
erythrocytes, since the nanoparticles are intended for intravenous administration. This assay is
indicative of effect of the nanoparticles on cell membrane integrity60. The blood cells were
incubated with NL-1 drug, blank nanoparticles and NL-1 loaded nanoparticles, and the absorbance
was measured as a function of hemolysis. PLGA nanoparticles have been found to have nonexistent hemolysis60, which was confirmed with the current assay. Thus, the formulation was
deemed safe for intravenous administration.
In summary, we report a successful formulation of the hydrophobic drug NL-1 into a PLGA
polymeric nanoparticle system, with a reasonable entrapment efficiency. Our data indicate that the
NL-1 loaded nanoparticles are effective in reducing oxidative stress arising from peroxide, and
improving the cell survival, in an in vitro stroke model.
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Figure 4.1: SEM images of blank PLGA nanoparticles (A) and NL-1 loaded PLGA nanoparticles
(B). Each unit on the scale represents 100 nm.
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Figure 4.2: Powder X-ray diffraction pattern for NL-1 drug, NL-1 drug and blank nanoparticles
physical mixture, blank PLGA nanoparticles, and NL-1 loaded PLGA nanoparticles.
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Figure 4.3: In vitro drug release profile for NL-1 drug and NL-1 from PLGA nanoparticles. Data
are plotted as total percent cumulative NL-1 released versus time.
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Figure 4.4: Cellular uptake of rhodamine nanoparticles in bEnd.3 cells. The flow cytometry
histograms (left) are representatives for cell control, blank nanoparticles, and each time point for
rhodamine nanoparticles. The graph (right) shows the quantification of rhodamine nanoparticle
uptake (***p<0.001, ****p<0.0001).

Figure 4.5: Energy dependence of nanoparticle uptake in bEnd.3 cells. Comparative flow
cytometry histograms (left) for cell control, and rhodamine nanoparticle uptake at 37°C and at 4°C.
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Graphical representation (right) of fluorescence intensities shows a significantly decreased uptake
at 4°C (****p<0.0001).

Figure 4.6: Mechanism of rhodamine nanoparticle uptake in bEnd.3 cells. Flow cytometry
histograms (left) are representatives of cell blank, rhodamine nanoparticles alone and with uptake
inhibitor treatments. The plot (right) indicates the quantification of fluorescence intensity with
respective uptake inhibitors, with genistein treatment showing significant reduction in uptake
(**p<0.01).
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Figure 4.7: Confocal microscopy z-stack images for cellular localization of rhodamine
nanoparticles in bEnd.3 cells showing nanoparticle localization in the cytoplasm. Cell nuclei
stained blue with DAPI (A and E), tubulin stained green (B and F), red rhodamine nanoparticles
(C and G). Images D and H show a merge of individual channels. Image I shows a super resolution
image of rhodamine nanoparticles being localized in the cytoplasmic tubulin cytoskeleton.
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Figure 4.8: Effect of NL-1 nanoparticle treatment on generation of hydrogen peroxide in bEnd.3
cells after 3 hours (A) and 6 hours (B) of OGD. The control was considered as 100% in order to
normalize values for multiple plates. The bottom panel shows a comparison in activity of NL-1
drug and NL-1 nanoparticles after 3 hours (C) and 6 hours (D) of OGD (***p<0.001, ****p<0.0001).
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Figure 4.9: Effect of NL-1 and NL-1 nanoparticles on apoptosis in bEnd.3 cells following
ischemia and reperfusion. Figures A-D are representative flow cytometry data for cell blank (A),
3 hour OGD (B), and 3 hour OGD with NL-1 (C) and 3 hour OGD with NL-1 nanoparticles (D).
Each figure shows four quadrants: live (bottom left), early apoptotic phase (bottom right), late
apoptotic phase (top right), and necrotic (top left) cell populations. Results are indicated in terms
of improvement in cell survival at 3 hours (E) and 6 hours (F) ischemic period, as well as the
reduction in late stage apoptosis after 3 hours (G) and 6 hours (H) of ischemia (*p<0.05, **p<0.01,
***
p<0.001, ****p<0.0001).
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Figure 4.10: Toxicity profile of PLGA nanoparticles. MTT cytotoxicity assay results indicate a
relatively safe profile for blank and NL-1 loaded PLGA nanoparticles at the highest concentration
of 10 mg/mL (A). NL-1, blank and NL-1 loaded nanoparticles showed a negligible hemolytic
activity (B).
Table 4.1: Particle size, polydispersity index and zeta potential of blank, NL-1 loaded and freeze
dried nanoparticles

Blank PLGA NP

NL-1 loaded
PLGA NP
Freeze dried
nanoparticles upon
re-dispersion

Particle Size (nm)

Polydispersity Index

Zeta Potential
(mV)

121.9 ± 20.6 (n=5)

0.17 ± 0.09

-16.8 ± 5.8

123.9 ± 17.1 (n=12)

0.27 ± 0.08

-26.2 ± 1.3

175.6 ± 6.8 (n=12)

0.10 ± 0.02

-26.2 ± 1.3
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Table 4.2: Summary of plots used for release modelling and the correlation coefficients obtained
for the corresponding plots
Model name

Graph plotted

R2 value

Zero order

% cumulative released vs time

0.9049

First order

Log(cumulative % drug remaining) vs time

0.9812

Cube root of % drug remaining vs time

0.9674

% cumulative released vs square root of time

0.9798

Log(% cumulative released) vs log(time)

0.9933

Hixson-Crowell cube root
model
Higuchi model
Korsmeyer-Peppas model
(first 60%)
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CHAPTER 5
Evaluation of the efficacy of NL-1 nanoparticles in an in vivo model
of cerebral ischemia and reperfusion injury

Chapter will be published with the tentative title:
MitoNEET ligand NL-1 loaded nanoparticles improve stroke outcomes in a
rat model of cerebral ischemia and reperfusion injury
Pushkar Saralkar, Aruvi Vijikumar, Shannon Brunzo-Hager, Gina Miller, Jason Huber and
Werner J. Geldenhuys
Journal: TBD

121

5.1. Introduction
Cerebral ischemia and reperfusion injury or stroke is a prime example of a condition with
a multimodal pathophysiology, making it the leading cause of permanent disability in the United
States1. The onset of a stroke occurs with an occlusion in blood supply to the cerebral regions of
the brain, which activates pathways for neuronal damage like a domino effect. The lack of oxygen
and glucose to the cells of the CNS leads to an energy crisis, causing neurodegeneration via
oxidative stress, apoptosis and neuroinflammation. Despite presenting multiple axes as therapeutic
targets, stroke therapy in the clinic has remained confined to the use of tissue plasminogen activator
(t-PA) to remove the occlusion. However, a greater impact could be from the complications that
arise from reperfusion of the ischemic tissue, during which the aforementioned complex interplay
between oxidative stress and inflammation predominates. Even with a timely treatment, stroke can
lead to a multitude of cognitive, sensory and motor sequelae2,3. This makes the assessment of
neurological functions an essential in the evaluation of any proposed stroke therapeutic4.
The hallmark feature of stroke is the advent of cerebral edema, which contributes to the
mortality associated with stroke5. Edema in stroke occurs in multiple phases and depends on the
stage of ischemia or reperfusion. Cytotoxic edema predominates in the ischemic phase, and
primarily causes cell swelling and damage. A direct consequence of cytotoxic edema is the
vasogenic edema that occurs mainly during the reperfusion phase, aided by the dysfunctional
BBB6,7. Vasogenic edema causes overall brain swelling with fatal consequences. Thus, there is an
immense need to address the issue of cerebral edema from a therapeutic standpoint, as reduction
in edema could be potentially life-saving. The major facilitator of vasogenic edema is the
dysfunctional BBB. Indeed, a host of factors such as MMPs, infiltrating leukocytes, cytokines and
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chemokines contribute to the loosening of BBB tight junctions8–10. This allows for extravasation
of plasma proteins, which are a component of the edema fluid, and can be used as markers for the
histological examination for BBB integrity. The BBB damage, while irreversible in the ischemic
core, could still be reversed in the penumbra region11,12. A therapeutic intervention that salvages
the BBB in stroke penumbra could aid in preventing edema in that region.
At the center of these pathways are the mitochondria. The outer mitochondrial protein
mitoNEET participates in redox processes and regulates cellular bioenergetics. Previously, we
have shown that the mitoNEET ligand, NL-1, has the potential to be a protective agent in ischemic
conditions. In vitro testing of a PLGA nanoparticle formulation of NL-1 in an ischemia-reperfusion
injury model has shown the drug to be effective in lowering oxidative stress and improving cell
survival. Formulation of NL-1 into a polymeric nanoparticle system could help improve drug
delivery to the target, prolong drug exposure and hence lower the dose required. In this chapter,
we aim to translate the in vitro results into a pre-clinical model of cerebral ischemia reperfusion
injury. We describe the use of a transient middle cerebral artery occlusion rat model to closely
mimic the conditions of ischemia and reperfusion. We report our findings for the effect of NL-1
and NL-1 nanoparticle therapy on stroke outcomes.
5.2. Materials and Methods
Materials
TTC and bupivacaine were purchased from Sigma-Aldrich (St. Louis, MO). 4-Hydroxynonenal
primary antibody (MAB3249) and HRP-linked anti-rat IgG secondary antibody (HAF005) were
purchased from R&D Systems (Minneapolis, MN). Nitrotyrosine primary antibody (NB11096877)
was purchased from Novus Biologicals (Littleton, CO). MitoNEET primary antibody
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(16006-1-AP) was purchased from ProteinTech Group (Rosemont, IL). Iba-1 primary antibody
(019-19741) was purchased from Fujifilm (Tokyo, Japan). Cytochrome c primary antibody
(D18C7) was purchased from Cell Signaling Technology (Danvers, MA). Caspase-3 primary
antibody (ab-4051) was purchased from Abcam (Cambridge, UK). GFAP primary antibody
(130300), anti-rabbit AlexaFluor 488 secondary antibody, anti-mouse AlexaFluor 568 secondary
antibody and anti-rat AlexaFluor 690 secondary antibody were purchased from Invitrogen
(Carlsbad, CA). The DAB substrate kit (SK-4100) was purchased from Vector Laboratories
(Burlington, ON). The Fluoromount-G mounting medium was purchased from Southern Biotech
(Birmingham, AL).
Methods
Study approval and drug treatment
Female Sprague-Dawley rats (22-24 months old) were purchased from Hilltop Laboratories
(Scottdale, PA) and housed under 12 hour light-dark conditions with food and water available ad
libitum. The West Virginia University Animal Care and Use Committee approved all criteria for
procedures prior to experimentation.
Study 1 assessed, neurological score, infarct volume, and hemispheric swelling at 24 hours post
MCAO. Study 2 evaluated histological changes at 72 hours post MCAO. Animals were randomly
assigned to 4 different treatment groups: control (PBS), 10 mg/kg NL-1, NL-1 nanoparticles with
a theoretical dose of 250 µg/kg and 250 µg/kg NL-1. The drug formulation was prepared by
dissolving a known amount of NL-1 (based on desired concentration) in methanol and evaporating
the solvent. The dried drug residue was reconstituted in ethanol (2% v/v final concentration) and
formulated with PBS and Tween 80 (2% w/v). All treatment was administered just before
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reperfusion via tail vein. To avoid biases, we also ensured that different treatments were performed
on the same day.
Surgical Procedure for MCAO
Rats underwent transient middle cerebral artery occlusion (MCAO) by an intraluminal suture
method13. All the surgical instruments and materials were autoclaved, and the surgical procedure
were performed under sterile conditions. In brief, we anesthetized mice with 4% isoflurane and
maintained anesthesia such that animals did not respond to toe pinch with 2% isoflurane via face
mask in a mixture of 30% oxygen and 70% nitrous oxide. A servo-controlled homeothermic
heating blanket, equipped with a rectal thermometer, was used to maintain body temperature at 37
°C. A 4.0 monofilament suture (Doccol, Sharon, MA) was inserted into the right external carotid
artery stump and advanced into the middle cerebral artery. We induced focal cerebral ischemia by
occlusion of the right middle cerebral artery for 120 min followed by reperfusion for 24 hour
(Study 1) or 72 hour (Study 2). Animals were singly housed and administered 0.5ml of saline to
help with dehydration after surgery. We also applied a local analgesia (bupivacaine 1 mg kg−1,
subcutaneously (s.c.) at the site of incision. The animals experiencing problems during the
induction of MCAO, such as excessive bleeding, and prolonged operation time were excluded.
Neurological Functional Assessment
Neurological functional assessments were carried out by an investigator blinded to treatment
groups at WVU rodent behavior core. The health screen and modified Neurological Severity
Scores (mNSS) were performed before stroke and 24h post MCAO to evaluate impairments in
motor, sensory, balance and reflex measures during the acute period. The scoring range was from
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0 to 20 point scale for health screen and 0-18 point scale for mNSS, with higher scores indicating
severe neurological injury.
Measurement of infarction volume by 2,3,5-triphenyltetrazolium chloride (TTC)
Measurement of the cerebral infarct size and infarct volume were performed by
2,3,5triphenyltetrazolium chloride (TTC; 2%) staining at 24 h following MCAO. The animals were
sacrificed, and the brains were isolated. 2 mm coronal brain slices were made using stainless rat
brain slicer matrix and stained for 15 min at 37 °C. Hemispheres were scanned on a flatbed scanner
and analyzed using Image J software. On each slice, the non-stained area (ischemic brain) was
outlined, and the infarct volume was calculated The corrected infarction volume (CIV) was
calculated using the formula: CIV= (CH/IH)*IA*d, where CH was the area of the contralateral
hemisphere in mm2, IH was the area of the ipsilateral hemisphere in mm2, IA was the infarct area
in mm2, and d was slice thickness (2 mm). CIV (%) = CIV/(CH*d). Edema index was calculated
as follows: Hemispheric swelling (%)=[1-(area of contralateral hemisphere/area of ipsilateral
hemisphere) ×100%].
Endogenous IgG staining
IgG immune staining was performed on rats that were subjected to 72 hour reperfusion. The slides
with 20 µm coronal brain sections were allowed to thaw at room temperature for about 15 minutes.
The sections were then fixed with addition of methanol for 3 minutes, upon which, the slides
washed once with 1X PBS. The blocking of endogenous peroxidases was performed with a mix of
3% v/v hydrogen peroxide and 4% v/v horse serum in PBS for 30 minutes. The slides were then
washed thrice with PBS for 5 minutes each. Subsequently, the brain sections were permeabilized
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in a solution of 4% v/v horse serum and 1% w/v TritonX-100 in PBS for one hour, followed by
washing thrice with PBS. The slides were then stained for IgG using the HRP-lined rat anti-IgG
secondary antibody solution made in 4% v/v horse serum in PBS (R&D Systems dilution: 1:500).
The secondary antibody incubation was carried out for 2 hours at room temperature, following
which, the slides were washed thrice with PBS. The DAB staining was performed using the DAB
staining kit. The staining solution was prepared by adding one drop of the DAB reagent to 1 mL
of the dilution buffer. The slides were incubated in this solution for 10 minutes, following which,
they were washed thrice with PBS. After the final wash, the slides were cover-slipped using the
Flouromount-G (Southern Biotech) mounting medium, and allowed to dry prior to imaging. The
slides were imaged by bright field microscopy using the Olympus MVX10 microscope at WVU
Imaging Core Facilities.
Immunofluorescence staining
Immunofluorescence staining was performed on rats that were subjected to 72 hour reperfusion.
The slides with 20 µm coronal brain sections were allowed to thaw at room temperature for about
15 minutes. The sections were then fixed with addition of methanol for 3 minutes, upon which, the
slides washed once with 1X PBS. The tissue permeabilization was carried out in a solution of 4%
v/v horse serum and 1% w/v TritonX-100 in PBS for one hour, followed by washing thrice with
PBS. The slides were then stained for the various markers using suitable primary antibody
cocktails, ensuring to not mix two primary antibodies from the same species. The following
primary antibodies were used: mitoNEET (Proteintech, rabbit, 1:200 dilution), cytochrome c (Cell
Signaling, rabbit, 1:200 dilution), caspase-3 (Abcam, mouse, 1:200 dilution), 4-hydroxynonenal
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(R&D Systems, mouse, 1 µg/mL), nitrotyrosine (Novus biologicals, mouse, 1:200 dilution), Iba-1
(Fujifilm, rabbit, 1:200 dilution) and GFAP (Invitrogen, rat, 1:500 dilution). The primary antibody
incubation was carried out in the dark at 4°C, overnight. The following day, the primary antibody
was removed and the slides were washed thrice with PBS, prior to secondary antibody incubation.
The following fluorescent secondary antibodies were used based on the primary antibody used the
previous day: anti-rabbit AlexaFluor 488 (Invitrogen, 1:1000 dilution), anti-mouse AlexaFluor 568
(Invitrogen, 1:1000 dilution) and anti-rat AlexaFluor 680 (Invitrogen, 1:1000 dilution). The
secondary antibody incubation was carried out for 2 hours in the dark at room temperature,
following which, the slides were washed thrice with PBS. After the final wash, the slides were
cover-slipped using the Flouromount-G (Southern Biotech) mounting medium, and allowed to dry
prior to imaging. The slides were imaged by fluorescence microscopy using the Olympus Slide
Scanner microscope at WVU Imaging Core Facilities.
Statistical analysis:
Statistical analysis of data obtained was carried out by GraphPad Prism 7.04 (GraphPad Software,
CA) using one-way ANOVA followed by Dunnett’s post hoc test for comparison of multiple
groups. The graphs were prepared using GraphPad Prism 7.04. Data are presented as mean with
standard deviations. A statistically significant difference between groups was considered if the p
value was <0.05.
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5.3. Results
Neurological functional assessment
The effectiveness of MCAO procedure in inducing a stroke and the efficacy of drug treatments to
improve stroke outcomes was determined using the neurological functional assessment tests,
24hours following tMCAO. This consisted of two tests: the general health screen (0-20 point score)
and the mNSS (0-18 point score), with a lower score indicating a better outcome. Figure 5.1(A)
shows the results for health screen wherein the scores are plotted for each group. All animals
showed a very low score between 0-1 pre-tMCAO (0.2 ± 0.6). The highest mean score of 12 ± 2.6
(n=8) was seen for the control group. NL-1 at 10 mg/kg showed a statistically significant
improvement in the health score of 9.2 ± 2.8 (n=9), compared to control. The higher dose NL-1
group at 10 mg/kg showed a lower mean health score compared to the low dose group at 250 μg/kg
(10.3 ± 2.9, n=6), though the differences were not statistically significant. NL-1 nanoparticles
significantly improved the health scores to 8.2 ± 2.6 (n=8), compared to control. The mean health
score for NL-1 nanoparticles was found to be lower than NL-1 drug by itself at the same equivalent
amount of NL-1, though no statistical significance was seen. For mNSS, a similar trend was
observed, shown in Figure 5.1(B). All animals showed a low pre-tMCAO score between 0-2 (0.7
± 1.1, n=23). The mean score was lowest for NL-1 nanoparticles among all groups (8.1 ± 1.6, n=6).
The mean mNSS score for NL-1 at equivalent dose of 250 μg/kg (11 ± 2.9, n=5) was found to be
comparable to the control group (11.2 ± 3.3, n=5). The mean score for high dose NL-1 at 10 mg/kg
was found to be 10.2 ± 1.7 (n=5) However, no statistical significance was seen for improvement
in mNSS scores for any treatment group compared to the control group.
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Effect of NL-1 treatment on brain infarcts
The 2 mm coronal sections obtained from the stroke animals were stained with TTC to reveal
infarcts in the brain. The infarct volume and hemispheric swelling were calculated for each of the
section for all the brains. Both, NL-1 at 10 mg/kg and NL-1 nanoparticles at a dose of 250 μg/kg
were able to significantly reduce the infarct volume, as shown in Figure 5.2(A). NL-1 at 10 mg/kg
reduced the infarct volume to 69.5% of control, while NL-1 nanoparticles reduced the infarct
volume to 49% of control. Similarly, both treatment groups significantly reduced the hemispheric
swelling in the brain compared to control treated rats, as shown in Figure 5.2(B). The hemispheric
swelling was reduced to 60.6% and 36.5% of control by 10 mg/kg and NL-1 nanoparticles,
respectively. The NL-1 nanoparticles significantly lowered the hemispheric swelling compared to
NL-1 at a 40-fold higher dose.
Immunohistochemistry
The possible extravasation of endogenous IgG from the brain vasculature was visualized by
immune staining brain sections of rats subjected to tMCAO and 72 hour reperfusion. Figure 5.3
shows the representative IgG stained brain sections for all treatment groups. A qualitative analysis
of IgG staining reveals a widespread staining on the ipsilateral side where the infarcts are present.
The stained area for NL-1 nanoparticle treated brain sections appears lower than that of the control
and 10 mg/mL NL-1 treatment groups. The IgG staining for NL-1 nanoparticle treated brain
appears to be confined to the central core of the stroke, with little spillover into the cortical region.
The greatest staining in the cortical regions was seen for the control group followed by 10 mg/kg
NL-1 treated group.
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Immunofluorescence staining was performed for qualitative analysis of the markers of oxidative
stress, inflammation and apoptosis after stroke. The images of brain section for all the markers are
compiled in a similar panel and include the treatments of (A) control, (B) 10 mg/kg NL-1 (C) NL1
nanoparticles at a theoretical NL-1 dose of 250 µg/kg and (D) 250 µg/kg NL-1. The brain sections
were stained for the proteins shown in the following figures: mitoNEET (Figure 5.4), nitrotyrosine
(Figure 5.5), 4-hydroxynonenal (Figure 5.6), cytochrome c (Figure 5.7), caspase-3 (Figure 5.8),
GFAP (Figure 5.9) and Iba-1 (Figure 5.10).
5.4. Discussion
We used an intraluminal suture tMCAO rat model for testing the in vivo efficacy of NL-1
loaded PLGA nanoparticles. Transient MCAO is a widely used model to mimic cerebral ischemia
and reperfusion injury14. About 70% of human ischemic stroke occur through occlusions in the
middle cerebral artery or its branches15. The procedure was carried out by intra-arterial suture
occlusion, which is a widely used technique to induce stroke in rodents. In this method, the suture
is inserted in the external carotid artery, and subsequently advanced into the internal carotid artery,
till the blood supply to the middle cerebral artery is occluded16. This approach is deemed better for
transient MCAO since it maintains the anatomic integrity required for repefusion17. This technique
has the advantages that it mimics human stroke with the formation of an ischemic penumbra,
produces reproducible infarcts, does not need the skull to be opened16,18,19. However, the tMCAO
technique does not model for the aspect of thromboembolism18. Moreover, the outcomes of the
procedure depend on the type and length of suture used. Nonetheless, tMCAO remains a gold
standard for generating a pre-clinical stroke model. We performed a 120-minute occlusion based
on literature, looking at the optimal occlusion period for fewer animal mortalities20–22.
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Four groups of treatments were used. The animals in control group received PBS. Since we
had previously performed a short pilot study with 10 mg/kg dose in mice, a group with this dose
was selected. The limitations with the volume of liquid that could be injected iv through the rat tail
vein and NL-1 entrapment efficiency in the nanoparticles placed a constraint on the NL-1
nanoparticle dose. The effective dose of NL-1 delivered through PLGA nanoparticles was about
250 µg/kg. Finally, we also included a NL-1 low dose group at 250 µg/kg, similar to the
nanoparticles.
The primary consequence of stroke is the immediate effect on the overall health of the
animals. We determined the effect of stroke and treatments on the animals using the health and
sickness scoring, prior to tMCAO and 24 hours following the surgery23–25. The sickness scoring
was carried out on a scale of 0-20, and is outlined in Table 5.1. The parameters evaluated include
the animal appearance, posture, body hydration, respiration and deficits in body weight and
temperature. Our results indicate that treatment with NL-1 at 10 mg/kg and NL-1 nanoparticles at
a dose of 250 μg/kg significantly improved the sickness score of the animals. NL-1 by itself at the
low concentration of 250 μg/kg had no significant improvement in the scores. Thus, nanoparticles
were able to induce an improvement in the subject health at a 40-fold lower dose. The possible
reason for this could be the efficient uptake of NL-1 loaded nanoparticles within the neuronal cells,
combined with the relatively slower release of the drug from the nanoparticles. The latter would
allow for the drug to act for a longer duration compared to the sudden exposure of NL-1 drug by
itself which could be prone to be metabolized faster26.
Stroke causes deficits in the sensory and motor functioning of the afflicted individual27.
The mNSS is one of the reliable and most commonly used composite tests for evaluating the
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neurological functioning of animals after stroke28,29. It uses a scale of 0-18 for rats. The mNSS is
called a composite test because it is an amalgamation of sensory (visual, tactile and
proprioceptive), motor (muscular movements), brainstem reflex and balance tests. The overall
score is the sum of scores received for individual tests. The specific mNSS tests performed in this
study are outlined in Table 5.2 and the include reflex tests, the walking test, the inverted test, the
paw-placement test and the beam balance test30. The advantage of using mNSS is that it allows for
a quick assessment of multiple aspects of stroke induced injuries31. mNSS is an effective test right
at 24 hours post-stroke and can also be used for a long term neurological evaluation of 30 or even
60 days29,32,33. However, the since the score is composite, it could lead to masking of neurological
deficits seen for one specific function or modality31. One way around this disadvantage could be
separation of the scores for each task. Further, mNSS scoring over a prolonged duration of up to
30 days could also help to provide conclusive mNSS results34,35.
We used mNSS to assess the behavior the following day of the tMCAO surgery, since
mNSS is frequently studied 24 hours post-stroke34–36. Our results indicate a general improvement
in the mNSS scores with treatment, as compared to control. The NL-1 nanoparticles had the lowest
means mNSS score amongst all treatments. NL-1 by itself at the equivalent dose has similar mean
score as the control group. Although, we don’t report statistically significant results, we think
improving on the animal numbers would help us achieve significantly reduced mNSS score for
NL-1 nanoparticles as compared to NL-1 by itself in equivalent (250 μg/kg) and possibly in high
dose (10mg/kg).
Triphenyltetrazolium chloride or TTC staining is one of the most commonly used
techniques to quantify brain infarcts. TTC is reduced by succinate dehydrogenase enzyme in the
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viable mitochondria to the red colored formazan, leaving the infarcts unstained37. TTC staining is
quick and reproducible. Although there have been questions raised about TTC staining possibly
overestimating infarct area, a study by Tureyen et al., found no significant difference in infarcts
quantified by TTC staining and by cresyl violet staining38. Infarct volume and hemispheric
swelling are two of the most important endpoints used for assessment of outcomes for a stroke
therapeutic39–41. Infarcts reveal the area of brain damage, whereas hemispheric swelling is
indicative of edema that accompanies the reperfusion injury. Our results show an improved stroke
outcome with both NL-1 (10 mg/kg) and NL-1 nanoparticles showing a significantly lowered
infarct volume and hemispheric swelling. In case of infarct volume, although no significant
difference was observed between NL-1 drug and NL-1 nanoparticles, it should be noted that NL1
nanoparticles were dosed at a 40-fold lower dose. A significant difference was seen between drug
and nanoparticles for hemispheric swelling, which shows the efficacy of PLGA nanoparticles in
reducing the drug dose.
After studying the effect of NL-1 treatment on the primary stroke outcomes, we moved to
looking at the status of different markers of damage following cerebral ischemia and reperfusion
injury. One of the hallmark features of stroke related damage is the dysfunctional and leaky BBB.
The BBB tight junctions are loosened, leading to extravasation of certain biomolecules such as
plasma proteins, that are otherwise impermeable42. One such commonly used plasma protein
surrogate marker to determine BBB leakiness after stroke is the endogenous IgG43–46. Our results
indicate an intense staining of brain sections treated with control and 10 mg/kg NL-1 in the
ipsilateral part of the brain, which received the stroke, with the drug treatment showing staining to
a lesser extent in the cortex, compared to the control. The NL-1 nanoparticle shows an overall
reduced staining compared to both the groups. Of note is the poor staining in the cortex of the
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nanoparticle treated brain. This could possibly indicate an improvement in the integrity of BBB in
the stroke penumbra, which could not be seen in control and NL-1 treated brain sections. Thus,
although qualitative, IgG staining of brain sections shows a possible rescue of BBB function by
NL-1 nanoparticles.
MitoNEET is the target for the NL-1 drug and it was necessary to look at its expression,
especially in the region of brain infarcts. For this purpose, we performed fluorescence
immunohistochemistry on the brain slices of animals that underwent 72 hour reperfusion, staining
for mitoNEET. A qualitative analysis reveals that mitoNEET not changed in the ischemic areas
sections of control as well as drug treated groups.
We also performed immunofluorescence staining for markers of the major pathways of
ischemia and reperfusion injury associated brain damage, including ROS-RNS, apoptosis and
neuroinflammation. Firstly, we looked at the expression of nitrotyrosine, which is a marker for
RNS specie peroxynitrite. Excess nitric oxide tends to react with superoxide radical to form the
highly cell permeable peroxynitrite. Peroxynitrite causes the nitration of tyrosine residues to form
nitrotyrosine47. Nitrotyrosine generation has been reported in ischemia and reperfusion injury48,49.
A qualitative analysis of NT stained brain sections reveal intense staining in the infarcted region.
The staining intensity was lowest for NL-1 nanoparticle treated brain compared to control and NL1
drug groups, indicating a possible lowering of NT generation due to a reduced infarct area. The
second marker for oxidative stress that we looked at was 4-hydroxynonenal, which is an aldehydic
by-product of lipid peroxidation50,51. This molecule has been reported to potentiate oxidative
cascades and cause impairment of glutamate transport in synapses52. The 4-hydroxynonenal
stained brain sections reveal an intense staining in the infarct area on the ipsilateral side for all
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groups. The intensities are lower for 10 mg/kg NL-1 and NL-1 nanoparticle treated brains, due to
the smaller infarct areas.
The next two sets of immune staining were performed for the two most commonly probed
markers of intrinsic apoptosis: cytochrome c and caspase-353,54. Cytochrome c is released into the
cytoplasm from the mitochondria due to mitochondrial swelling and damage to the mitochondrial
membrane potential, wherein it activates the initiator caspases55. Caspase-3 is an important effector
caspase which mediates apoptosis. The staining of brain sections could not indicate a trend with
cytochrome c expression in any of the groups. On the other hand, a more intense staining was seen
for caspase-3 in the infarcts of all the groups on the ipsilateral side.
We then turned to determining the expression of markers of inflammation in the brains
sections. Astrocytes are often activated in the inflammatory mechanisms surrounding ischemia and
reperfusion injury56, and activated astrocytes overexpress GFAP, which is commonly used as an
inflammatory marker in stroke57,58. A qualitative analysis of GFAP stained sections reveals
widespread staining on the ipsilateral side of the brain. The GFAP staining was seen to be confined
to the core infarct regions for 10 mg/kg NL-1 and NL-1 nanoparticle treated brain sections. NL-1
nanoparticles had the smallest area of staining, possibly indicating lack of astrocytic activation in
the stroke penumbra upon NL-1 treatment. Finally, we looked at the expression of microglial
calcium-binding protein Iba-1. Iba-1 has been found to be upregulated in activated microglia in
stroke and Iba-1 immunostaining has been a used as a means to identify activated microglia59,60.
Iba-1 staining images indicate an intense staining in the region of infarcts for all the groups, with
lesser intensity seen for NL-1 nanoparticles due to a reduced infarct size.
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In summary, this chapter describes the preliminary in vivo efficacy studies performed for
NL-1 loaded PLGA nanoparticles. We describe a rat tMCAO model for mimicking cerebral
ischemia and reperfusion injury. We found that NL-1 nanoparticles have the potential to improve
neurological outcome following a stroke. NL-1 nanoparticles were also effective in reducing the
infarct sizes and edema formation in the brain, helping to lower the dose needed to be administered
to achieve therapeutic effects. We also report our attempts to visualize the integrity of BBB and
expression of markers contributing to cell damage in stroke.
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Figure 5.1: Neurological assessment of animals pre-tMCAO and post treatment with control, 10 mg/kg
NL-1, 250 µg/kg NL-1 and NL-1 nanoparticles. (A) Health screening and (B) mNSS scoring (*p<0.05,
**
p<0.01).

Figure 5.2: Effect of NL-1 therapy on infarct volume and edema (A) Representative TTC stained brain
sections for control, 10 mg/kg NL-1, 250 µg/kg NL-1 and NL-1 nanoparticles. Effect of NL-1 and NL-1
nanoparticle treatment on (B) infarct volume and (C) hemispheric swelling after 2 hour tMCAO and 24
hour reperfusion ($$, ##p<0.01, ***, ###p<0.001, ****, ####p<0.0001).
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Figure 5.3: Representative sections for IgG extravasation staining for (A) control, (B) 10
mg/kg NL-1 and (C) NL-1 nanoparticles after 2 hour tMCAO and 72 hour reperfusion.
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Figure 5.4: Representative sections for mitoNEET immune staining for (A) control, (B) 10
mg/kg NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion.
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Figure 5.5: Representative sections for nitrotyrosine immune staining for (A) control, (B) 10
mg/kg NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion.
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Figure 5.6: Representative sections for 4-hydroxynonenal immune staining for (A) control,
(B) 10 mg/kg NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72
hour reperfusion.
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Figure 5.7: Representative sections for cytochrome c immune staining for (A) control, (B) 10
mg/kg NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion.
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Figure 5.8: Representative sections for caspase-3 immune staining for (A) control, (B) 10
mg/kg NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion.
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Figure 5.9: Representative sections for GFAP immune staining for (A) control, (B) 10 mg/kg
NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion.
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Figure 5.10: Representative sections for Iba-1 immune staining for (A) control, (B) 10 mg/kg
NL-1, (C) NL-1 nanoparticles and (D) 250 µg/kg NL-1 after 2 hour tMCAO and 72 hour
reperfusion

Table 5.1: Health screen scoring table
Parameter

Observation

Score
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General
Appearance

Posture

Body Condition

Respiration

Body
Temperature

Body Weight

Spontaneous
Locomotion/Social
Interaction

Normal
Groomed, healthy appearing fur, pink mucous membranes and ear lobes

0

Mild Abnormal
Mildly rough/scruffy/dull fur, slightly less well-groomed, light pink mucous membranes/ear lobes, minimal
porforin staining, slightly squinted eyes

1

Moderate Abnormal
Rough/scruffy fur, piloerection, poor grooming, pale mucous membranes and ear lobes, squinted eyes

2

Severe Abnormal
Very rough fur, no evidence of grooming, white mucous membranes and ear lobes, substantial porforin
staining, severely squinted or closed eyes

3

Normal

0

Slight Hunch
Spine slightly curved

1

Moderate Hunch
Spine curved, paws slightly under body

2

Severe Hunch
Spine dramatically curved, paws tucked under body, head angled downward

3

Normal

0

Thin
Slight segmentation of vertebrae, dorsal pelvic bones are more prominent, slight dehydration (skin pinch
test response is slightly delayed)

1

Emaciated
Prominent vertebrae and skeletal bones that are readily palpable, dehydrated (skin pinch test results in skin
remaining tented)

2

Normal

0

Altered
Increased rate and/or effort

1

Abnormal/Distressed
Very increased rate or gasping/labored breathing, irregular

2

Normal/No change

0

1-4 degree C

1

5-8 degree C

2

9-12 degree C

3

0-5% change

0

5.1-10% change

1

10.1-15% change

2

15.1-20% change

3

> 20.1% change

4

Normal
Active and interacting with cage-mate(s)

0

Mild Abnormal
Still spontaneous activity and some peer interaction but reduced

1

Moderate Abnormal
Lethargic (may need probing via tapping on cage or cage tilt) and minimal peer interaction

2

Severe Abnormal
Immobile and no peer interaction

3
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Table 5.2: mNSS screen scoring table

Subtest

Score

1. Reflex test

3

Corneal Reflex – lack of eye blink when cornea is touched

1 (0.5/eye)

Pinna Reflex – lack of head shake when pinna is touched

1 (0.5/ear)

Startle – lack of jumping, freezing, moving when loud noise is heard

1

2. Walking test

3

Normal

0

Inability to walk straight

1

Circling/falling toward paretic side

2

Immobile (despite probing)

3

3. Placing test

3

Visual- lack of placement

1 (0.5/paw)

Tactile – lack of placement

1 (0.5/paw)

Proprioceptive – lack of placement

1 (0.5/paw)

4. Beam balance test

6

Balances steadily or traverses beam to clamp

0

Grasps sides of beam but is generally steady

1

Balances unsteadily, hugs beam and/or 1 limb slips/falls down

2

Balances unsteadily, hugs beam, 2 limbs slip/fall down

3

Attempts to balance but very unsteady, falls under beam but recovers

4

Attempts to balance but spins, clings to underside of beam

5

No attempts to balance

6
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5. Inverted test

3

Forelimb flexion or limb not moving to aid with balance

1

Hindlimb flexion or limb not moving to aid with balance

1

Head moved more than 10 degrees from vertical center or persistent spin

1

Total

18

CHAPTER 6
Conclusions and Future directions
6.1. Conclusions
In summary, this dissertation describes the journey of establishing the mitoNEET ligand
NL-1 as a potential therapeutic for treatment of cerebral ischemia reperfusion injury. Stroke is a
condition with a very complex pathophysiology, involving multiple axes resulting in cerebral
tissue damage. This is one of the primary reasons for the paucity of effective therapeutic options.
Indeed, the thrombolytic t-PA is the only available drug to undo the occlusion to blood flow.
However, a t-PA induced resumption of blood supply might not provide any respite, as reperfusion
can trigger a cascade of events creating an environment of increased oxidative stress and
inflammation. The BBB, responsible for protecting the brain from xenobiotics, undergoes a
breakdown with time, leading to fatal edema in the brain.
With the ever looming challenge of developing newer treatment alternatives for this leading
cause of permanent disability, we investigated targeting a hitherto relatively unexplored drug
target. MitoNEET, is an outer mitochondrial protein that is involved in regulation of cellular
bioenergetics. It was discovered due to its binding of the anti-diabetic thiazolidinedione drugs such
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as pioglitazone. To date, mitoNEET has no known endogenous ligand, but several reports implicate
its involvement in metabolic and redox processes. We previously developed NL-1, a ligand for
specific for mitoNEET. The glitazones don’t offer a plausible option due to their extraneous
hypoglycemic actions. Here, we first reported the specificity of NL-1 for mitoNEET, proving that
it had no redundant anti-diabetic effects. We then evaluated our hypothesis that NL1 could be have
protective actions in ischemic conditions. Our results indicated that NL-1 could address the
elevated oxidative stress and improved cellular respiration in an ischemic environment.
We then proceeded with formulation of NL-1, a drug with poor aqueous solubility, into a
polymeric nanoparticle system using the biodegradable polymer PLGA. After a successful
formulation with acceptable drug entrapment efficiency, we evaluated the nanoparticle uptake in
to the cells. More importantly, we tested our formulation on an in vitro model of ischemia and
reperfusion injury. Our formulation successfully lowered the peroxide generation and improved
cell survival by decreasing the percentage of cells in an apoptotic phase. The successful in vitro
results helped to establish NL-1 as a potential stroke therapeutic.
However, for any therapeutic to gain substance, it is important that the in vitro success can
translate into in vivo effects. To that effect, we tested NL-1 nanoparticles in an in vivo rat tMCAO
model, that closely mimics ischemia and reperfusion injury. The NL-1 formulation could show
efficacious results in vivo, by improving general health of stroke animals. The therapy also reduced
the infarct formation in the brains, and significantly decreased the extent of hemispheric swelling,
which could lead to hemorrhage, and is a fatal consequence of stroke. Our formulation was able to
reduce the dose of NL-1 required to produce these effects, by a possible prolonged drug exposure
and effective drug delivery.
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This work has helped to lay down a platform for pursing NL-1 as a therapeutic for stroke,
which suffers from a dearth of effective clinical translation of therapeutics. We have explored a
new drug candidate for a novel target which is the need of the hour for the mitigation of stroke
pathophysiology. These promising results could give an impetus for future research into using NL1 and mitoNEET as neuroprotective agent and target, respectively.
6.2. Future directions
Future studies that can be planned based on this preliminary research include:
1. Firstly, the role of mitoNEET itself could be brought into focus. Future studies should focus
on development of vivo models with mitoNEET knockdown and overexpression. The
effect of these genetic variations could then be evaluated on the levels of mediators of
stroke damage such as ROS, apoptosis and inflammation. This project has opened the
possibility of mitoNEET being a factor in more than one of the axes that contribute to
neurodegeneration. Such studies would help make mitoNEET a mainstream therapeutic
target.
2. The definitive mechanism of action of NL-1, or any mitoNEET ligand in general has not
been established yet. This work did not explore the exact molecular pathways involved in
the protective effects of NL-1. A well-established mechanism of action would lend
substance to NL-1 as a therapeutic. A more extensive evaluation of markers of oxidative
stress, apoptosis and neuroinflammation is warranted.
3. Subsequent structure-activity studies on NL-1 could serve as the progenitor molecule to
develop more TZD or non-TZD ‘me-too’ drugs with improved physicochemical properties.
Some of the promising analogs that could be evaluated as stroke therapeutics include CI987
and TT01001.
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4. Performing a prolonged study for the neurological deficits would help to determine long
term effects of NL-1 treatment. A robust study with periodical assessment of neurological
scores and survival over 30 days can be performed.
5. Lastly, many neurodegenerative diseases tend to share some common features in their
pathophysiology. It would be worthwhile to investigate NL-1 as a global neuroprotective
agent, in conditions such as traumatic brain injury or Alzheimer’s disease.
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